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A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF LORNOXICAM 
AND DICLOFENAC AS POSTOPERATIVE ANALGESICS AFTER 
MASTOIDECTOMY SURGERY 
   
                                                                          ABSTRACT 
INTRODUCTION - Postoperative pain sensation is due to the surgical trauma that 
occurs during manipulation of tissues. Lornoxicam is a nonselective NSAID and it 
belongs to oxicams with analgesic and anti-inflammatory properties and it has rapid onset 
of action when compared to other oxicams and has short halflife. Diclofenac sodium is a 
cyclooxygenase inhibitor and has been used in the management of postoperative pain for 
many years. It accumulates in the inflamed tissue and the concentration are maintained 
higher in plasma for many hours and its active metabolite acts as an analgesic. Aim of the 
present study is to evaluate the efficacy and safety of the analgesic, Lornoxicam when 
compared to Diclofenac in the management of postoperative pain following 
mastoidectomy surgery. MATERIALS AND METHODS – In this prospective single 
blinded study, 80 patients underwent mastoidectomy surgery and they were randomized 
in to two parallel groups. Group A received injection lornoxicam 8mg and group B 
received injection diclofenac 75mg given intramuscularly twice daily for the 3 
consecutive days. The primary parameter was to analyse the pastoperative pain using 
Visual analogue scale and Wong Bakers scale. The rescue medication used was injection 
paracetamol 300mg intramuscular. The secondary parameters are the usage of rescue 
medication and time to use rescue medication by the patients in each study group. 
Adverse events reported by the subject or noted by the clinician during the each follow-
up visit were recorded.RESULTS – The primary efficacy parameter showed significant 
reduction in the postoperative pain in the lornoxicam group than the diclofenac group ( p 
value <0.05) throughout the study. 3 (7.5% ) patients required rescue medication in 
lornoxicam group and 11 (27.5%) patients required rescue medication in diclofenac 
group.   Significantly more patients required rescue medication in diclofenac group than 
the lornoxicam group. The mean time required to use rescue medication in lornoxicam 
group was 7.33±2.21 hours and for diclofenac group it was 7.09 ± 3.36. Renal and liver 
function parameters did not show any significant difference between preoperative and 
postoperative values. No serious adverse event was noted in two groups.CONCLUSION 
- Based on the results of our study we conclude that injection lornoxicam 8mg given 
intramuscularly is a better analgesic when compared to injection diclofenac 75 mg given 
intramuscularly in efficacy and tolerability in the management of   postoperative pain 
following mastoidectomy surgery. 
KEYWORDS – Postoperative pain, Lornoxicam, Diclofenac, Mastoidectomy surgery. 
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INTRODUCTION 
 Pain in postoperative period is associated with any type of surgery. The 
severity of the postoperative pain is related to the type of the surgery and relief 
from pain is an essential component of postoperative patient care. 
Postoperative pain sensation is due to the surgical trauma that occurs during 
manipulation of tissues
1
. 
         Mastoidectomy surgery causes continuous distress to patient hampering 
recovery time and affects the outcome of the patient. Postoperative pain being 
not relieved promptly increases the stress response of the immune system 
leading to delayed wound healing and prolonged hospitalisation
2
. Early and 
effective postoperative pain relief can reduce the postoperative pain related 
complications and decrease the duration of hospitalisation by enabling early 
ambulation
3
. 
             It has been observed that postoperative pain in 20 to 40% of patients is 
of moderate intensity and pain in 50-70% is severe in nature
4
. Drugs used in 
the management of postoperative pain must be effective and safe with minimal 
adverse effects
1
. In the management of postoperative pain, opioids are the main 
stay after surgical procedures, however it has many adverse effects like 
respiratory depression, nausea, vomiting , constipation. On the other hand non-
steroidal anti-inflammatory drugs (NSAIDS) are used in the postoperative pain 
management to avoid the adverse effects associated with the opioids
5
. 
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Lornoxicam is a nonselective NSAID and it belongs to oxicams with 
analgesic and anti-inflammatory properties. Besides its inhibitory effects on 
cyclooxygenase (COX1 and COX2) it also increases endogenous dinorphin and 
beta endorphin levels promoting central analgesic and anti-inflamatory effects
4
. 
Lornoxicam has pharmacokinetic and pharmacodynamic properties similar to 
piroxicam and it is as effective as morphine, pethidine and tramadol in 
managing pain after major surgeries
5
.  
Lornoxicam has rapid onset of action when compared to other oxicams 
and has short halflife
1
.  Lornoxicam has better safety profile than diclofenac 
with regards to renal and hepatic function tests and it has been used 
successfully in the management of postoperative pain
6
.  
Diclofenac sodium is a cyclooxygenase inhibitor and has been used in 
the management of postoperative pain for many years. It accumulates in the 
inflamed tissue and the concentration  are maintained higher in plasma for 
many hours and its active metabolite acts as an analgesic
7
. 
There is lack of clinical trials comparing Lornoxicam and Diclofenac in 
the management of postoperative pain. Thus the present study was done to 
evaluate the analgesic efficacy and safety of Lornoxicam when compared to 
Diclofenac  in postoperative patients following Mastoidectomy surgery.                        
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REVIEW OF LITERATURE 
The management of pain always remains a challenge to the clinicians
8
. 
A revolution has occurred in the management of acute post-operative pain 
during the past two decades
9
.  Inspite of understanding the pathophysiology of 
pain it is difficult to control pain
8
. Pain perception is the series of 
electrochemical events following tissue damage or injury. Pain can be 
effectively relieved in 90% of patients but only 20% of patients achieve 
effective pain relief
10
. 
 Definition of pain: Pain is defined by International Association for the study 
of pain (IASP) as an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage or described in terms of tissue damage or 
both
11
. 
The purpose of pain is protective mechanism for the body and it occurs 
whenever any tissues are being damaged
12. Pain is one of nature’s earliest signs 
of morbidity and it stands pre-eminent among all the sensory experiences by 
which humans judge the existence of disease with in themselves
13
. 
Pain can be classified as acute pain, chronic pain and malignant pain. 
Acute pain is due to injury, surgery, illness, trauma or painful medical 
procedure. Pain lasts for short period and disappears after treating the 
underlying cause or after adequate time for healing. Chronic pain is a persistent 
pain not associated with malignancy or acute pain caused by trauma or surgery. 
Malignant pain is associated with carcinoma
14
.
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HISTORY OF PAIN 
In prehistoric period there was belief that intrusion of objects or spirits 
in to the body is the source of unpleasant and distressful experience. The 
chinese canon of medicine 2600BC gave major importance to the heart, 
presumed to regulate life and the brain was ignored. Aristotle believed touch to 
be closely related to pain and he recognized the relationship between tissue 
injury and pain. Herophilus 335-280BC proposed brain to be organ of 
consciousness and sensation. Galen 130-280 proposed that brain is the 
paramount organ for consiousness and sensation.  
Early in Rennaissance, Lenonardo da vinci appreciated the role of 
peripheral nerves in carrying messages from to and from the body. Physicians 
in 3
rd
 century BC proposed nerves have specific functions. Charles Bell (1774-
1842) proposed the differences in function between the dorsal and ventral roots 
of the mammalian spinal cord. Francois Megendie proposed the function of 
spinal roots. Bell and Megendie together discovered the function of spinal cord 
and pain mechanism. 
In 1858 Moritz Schiff student of Megendie described effects of spinal 
cord lesions in dogs and cats and proposed separate spinal pathways for tactile 
stimulation, movement detection, pain and temperature sensation
15
.     
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THEORIES OF PAIN  
For more than centuries the views on nature of pain sensation have been 
dominated by many theories. 
1. Specificity theory – This theory was given by Von Frey. He declared 
that the skin consisted of a mosaic of discrete sensory spots and that 
each spot when stimulated gave rise to one sensation either pain, 
pressure, warmth or cold. In his view each of these sensations had a 
distinctive end organ in the skin and each stimulus specific end organ 
was connected by its own private pathway to the brain. 
2. Summation theory - This theory was given by Gold Scheider according 
to him there were no distinctive pain receptors and the sensation of pain 
was the result of the summation of impulses excited by pressure or 
thermal stimuli applied to the skin originally called as intensivity theory, 
later known as the pattern or summation theory. 
3. Gate control theory – In 1965 Melzack and Wall propounded the most 
important “ gate control ” theory, they observed that in decerebrate and 
spinal cats, the peripheral stimulation of large myelinated fibers 
produced a negative dorsal root potential and  stimulation of small C  
pain  fibers caused positive dorsal root potential. They postulated that 
these potentials were reflection of presynaptic inhibition or excitation 
which modulated the activity of secondary transmitting neurons in the 
dorsal horn. This modulation was mediated through inhibitory cells. 
They also emphasised that pain impulses from dorsal horn must be 
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under the control of descending system of fibers from brainstem, 
thalamus and limbic lobes.
16,17,18
 
CLASSIFICATION OF PAIN  
1. Nociceptive pain: It is due to tissue irritation, impending injury or 
actual injury. Nociceptors are  activated in the affected area and 
transmits signals via the peripheral nerves and spinal cord to the brain, 
activating   the complex spinal reflex (withdrawl) followed by 
perception, cognition and affective response and voluntary action 
.Nociceptive pain is time limited and respond well to treatment with 
opioids. 
2. Neuropathic pain: It is due to injury or malfunction of the nervous 
system in the peripheral or central nervous system. Pain persists for 
months or years beyond apparent healing of any damaged tissue. 
Neuropathic pain is chronic and responds less to treatment with opioids. 
3. Psychogenic pain: It is due to psychological factors leading to 
exaggerated or histrionic presentation of the pain problem. 
4. Mixed category pain: It is caused by complex mixture of nociceptive 
and neuropathic factors .Initial nervous system dysfunction or injury 
trigger the neural release of inflammatory mediators and subsequent 
neurogenic inflammation. 
Postoperative pain can also be divided in to acute pain and chronic pain. 
Acute pain is experienced immediately after surgery up to seven days. Chronic 
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pain lasts for more than three months after surgery. Acute and chronic pain 
arise from cutaneous deep somatic or visceral structures. 
It is important to distinguish between first pain and second pain .First 
pain is sharp and pricking. It localises to well defined part of the body surface 
mediated by specific nociceptors. Second pain is dull aching poorly localized 
due to stimulation of receptors in the main tissues
12
.  
 PHYSIOLOGY OF NOCICEPTION 
The purpose of pain is mainly protective mechanism for the body it 
occurs whenever tissues are damaged. Pain is classified in to fast pain and slow 
pain. 
a. Fast pain – It is also called as sharp pain, pricking pain, acute pain, electric 
pain. Pain is felt within 0.1 sec after the pain stimulus is applied. Felt when 
skin is cut with a knife or needle stick in to the skin.
12
 This activity is due to the 
activation of  A  pain fibers
11
   
b. Slow pain – It is also called as slow burning pain, aching pain, throbbing 
pain, nauseous pain, chronic pain. Pain begins after one second or more and 
then increases slowly over many seconds and sometimes even minutes. Pain is 
due to tissue destruction. It occurs in skin and in any deep tissue or organ.
12 
It is 
due to  activation  in the C pain fibers
11
.  
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 NOCICEPTORS:  
Main organs in the periphery like skin and subcutaneous structures, 
joints and muscles possess sensory receptors activated by noxious insults. The 
nociceptors are simply the free nerve endings of primary sensory neuron. Three 
main class of nociceptors are thermal, mechanical, polymodal and the fourth 
class silent nociceptors. 
Thermal nociceptors – It is activated by extremes of temperature >45 C or < 5 
C. They are the peripheral nerve ending of small diameter , thinly myelinated 
Aδ axons. 
Mechanical nociceptors – It is activated by intense pressure applied to the 
skin.They are also the nerve endings of Aδ axons. 
Polymodal nociceptors – It is activated by high intensity mechanical , 
chemical or thermal stimuli .They are found at the ends of small diameter in 
myelinated C axons. 
Silent nociceptors – They are found in the viscera not activated by noxious 
stimuli . Inflammation and various chemical agents reduce the firing 
threshold
19
. 
The membrane of the nociceptor contains receptors that convert the 
thermal, mechanical or chemical energy of noxious stimuli in to depolarizing 
electric potential. One such receptor is a member of large family called 
Transient Receptor Potential (TRP) ion channel. 
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TRPV1 expressed by nociceptive neurons and mediate the pain 
producing actions of capsaicin, the active ingredient of hot peppers and many 
other pungent chemicals . TRPV1 channel is also stimulated by noxious 
stimuli, thermal stimuli and reduction in pH. 
TRPV2 channel is expressed in Aδ fiber terminals and inactivated by 
very high temperature. TRP M8 channel is activated by low temperature and by 
chemicals like menthol. 
Nociceptors selectively express tetrodotoxin resistant Na channel. 
SCN9A Na channel gene plays an important role in perception of pain. 
Mutation of the gene reveal rare pain insensitive individuals. 
Nociceptors express an ionotropic purinergic receptor PTX3 that is 
activated by adenosine tri phosphate released from peripheral cell after tissue 
damage. Mas related G protein coupled receptor family are activated by peptide 
ligands that sensitise nociceptors to other chemicals released in their local 
environment. 
The uncontrolled activation of nociceptors is associated with several 
pathological conditions
20 21
. Allodynia and hyperalgesia are two common pain 
states that reflect changes in nociceptor activity.  
Hyperalgesia – Increased amount of pain associated with mild noxious 
stimulus. Patient report persistent pain in the absence of sensory stimuli. 
10 
 
Allodynia – Pain associated with non-noxious stimulus or spontaneous pain 
without any precipitating stimulus
22
  
PERSISTENT PAIN  
Persistent pain can be  subdivided in to two classes 
a. Nociceptive pain – It is due to activation of nociceptors in skin or 
soft tissues in response to tissue injury. 
b.Neuropathic pain – It is due to direct injury to nerve in peripheral or 
central nervous system accompanied by burning or electric sensation.  
Anesthesia dolorosa –It is a phenomenon in which pain occur without 
peripheral stimulus
20
.  
PATHWAY OF PAIN  
Sense organ for pain are the naked nerve endings found in every tissues 
of the body. Pain impulses are transmitted to the CNS by two fibre system. 
1. Small Myelinated typeA delta fibers 2-5µm in diameter conduct at 
the rate of 12-30m/s. 
2. Unmyelinted  typeC fibre 0.4 – 1.2 µm in diameter conduct at the 
rate of 0.5 – 2m/sec 
Both the fibers end in the dorsal horn, Aδ in lamina 1 & 5 and dorsal 
root C fibers terminate in lamina 1&2. Synaptic transmitter secreted by primary 
afferent fibers for mild pain is glutamate and for severe pain is substance P
11
.  
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The primary afferents are classified by their diameter, degree of 
myelination and conduction velocity. Aδ and C fibers are primary nociceptors. 
Primary afferent nociceptors respond to stimuli like a pinch, changes in pH, 
acidic environment, chemical irritants, ATP, serotonin, bradykinin and 
histamine
19
 . 
MODULATION IN NOCICEPTIVE PATHWAY : 
There is a dual pathway for transmission of pain signals in to the brain. 
The two pathway for two different types of pain are  
1. Acute sharp pain pathway 
2. Slow chronic pain pathway 
  Peripheral pain fibers - Fast and slow signals are transmitted in 
peripheral nerves to the spinal cord, type Aδ for acute sharp pain signals and  
type C fibers  for slow chronic type pain signals. On entering spinal cord from 
dorsal spinal root the pain fibers ascend or descend. 
Acute sharp pain pathway – The fast type A δ pain fibers terminate at dorsal 
horns in lamina 1 and 5 and excite the second order neuron .Second order 
neuron send long fibers immediately to the opposite side of the cord in the 
anterior commissure and the to the brain in the lateral division of anterolateral 
sensory pathway. 
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After entering the brain stem, three quarters to nineteenths of all pain 
fibers terminate in the reticular formation of the medulla, pons and 
mesencephalon. . From these areas higher order neurons are transmitted to the 
thalamus, hypothalamus  and areas of diencephalon and cortex of the brain.  
Small portion of fast acute pain fibers terminate in ventrobasal complex 
and posterior nuclear group of thalamus along with sensory fibers from dorsal 
column lemniscal pathway. From there signals are transmitted to thalamus and 
somatosensory cortex. Signal to cortex is important for localizing the pain  
Slow chronic pain pathway – Type C fibers transmit slow pain signals 
terminate in lamina 2 and 3 of the dorsal horn called substansia gelatinosa . 
One or more additional short fibre neurons terminate in lamina 5. These fibers 
pass through anterior commissure to the opposite side and then upward to the 
brain via the lateral division of anterolateral sensory pathway. Few of these 
fibers do not pass ipsilaterally to the brain. In the brain terminate entirely in the 
reticular formation of the brain stem and in to the intra laminar nuclei of the 
brain stem and then finally to the cerebral cortex of the brain.  
Surgical incision produces tissue injury with consequent release of 
histamine and inflammatory mediators like peptide (bradykinin) , lipids 
(prostaglandin), neurotransmitter (serotonin), neurotrophins (nerve growth 
factor). The release of inflammatory mediators activates peripheral nociceptors 
which initiate transduction and transmission of nociceptive information to the 
central nervous system. Noxious stimuli are transduced by peripheral 
13 
 
nociceptors and transmitted by Aδ  and C nerve fibre from peripheral visceral 
and somatic sites to dorsal horn of spinal cord where integration of peripheral 
nociceptive and descending inhibitory modulatory input (serotonin, nor 
epinephrine, GABA and enkephalin) or descending facilitatory input 
(cholecystokinin, excitatory aminoacid, dynorphin) occurs. Some impulse pass 
to ventral and ventrolateral horns to initiate spinal reflex responses. Other 
signals are transmitted to the higher centre through the spinothalamic and 
spinoreticular tracts where they produce cortical response to generate the 
perception of pain
23
.  
SENSITISATION  
                         When intense repeated or prolonged stimuli are applied to 
damaged or inflamed tissue the threshold for activating primary afferent 
nociceptors are lowered  and the frequency of firing is higher for all intensities 
of the stimuli .Inflammatory mediators like prostaglandins, leukotrines, 
bradykinin, nerve growth factor contribute to sensitization
19
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FIGURE – 1 
FLOW DIAGRAM OF TISSUE INJURY EVOKED NOCICEPTION
24 
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PAIN CONTROL SYSTEM IN THE BRAIN AND SPINAL CORD  
The degree to which each person reacts to pain varies, due to the 
capability of brain to control the degree of input of pain signals to the nervous 
system by activation of pain control system called an analgesia system. 
            It consist of three major components and other accessory components  
1. Periaqueductal grey area of the mesencephalon and upper pons 
surrounding the aqueduct of sylvius neurons. From here signals are sent 
to Raphe Magnus nucleus. 
2. Raphe Magnus nucleus is a thin midline nucleus located in the lower 
pons and upper medulla. From here signals are transmitted down to 
spinal cord. 
3. Pain inhibitory complex located in the dorsal horn of the spinal cord, at 
this point pain signals can be blocked before they are relayed to the 
brain. 
Electrical stimulation in the periaqueductal grey especially the 
periventricular nuclei in the hypothalamus and to a lesser extent the medial 
forebrain bundle in the hypothalamus can suppress pain. The main 
neurotransmitter substance involved in analgesia system is encephalin and 
serotonin. 
Nerve fibers derived from the periventricular nuclei and periaqueductal 
grey secrete encephalin at their nerve ending. These fibers end in the Raphe 
magnus nucleus release enkephalins. Fibers originating from this nucleus 
16 
 
terminate in the dorsal horn of the spinal cord secrete serotonin at their endings 
.The serotonin in turn acts on local cord neurons that secrete enkephalins. 
Enkephalins produce presynaptic inhibition of incoming pain fibers to laminae 
1 through 5 in dorsal horns. 
Analgesia system can block pain signal at the initial entry point to the 
spinal cord and also at other points in the pain pathway especially in the 
reticular nuclei in the brain stem and in the intralaminar nuclei of the thalamus. 
Pain analgesia system is capable of blocking both fast sharp type pain and slow 
burning aching type pain
11,12
. 
In a study it was discovered that injection of extremely minute quantities 
of morphine in to periventricular nucleus around the third ventricle of the 
diencephalon or in to periaqeductal grey of brain stem produce extreme degree 
of analgesia. Subsequent studies have shown that morphine acts at other points 
in the analgesia system including Raphe Magnus nucleus and dorsal horns of 
spinal cord
12
. 
A. ENDOGENOUS OPIOIDS 
An agent found with in the brain that act through an opioid receptor is an 
endogenous opioid . Principal endogenous opioid peptides are  
1. Enkephalin 
2. Endorphins 
3. Dynorphins 
4. Endomorphins 
17 
 
5. Nociceptin peptide 
Common properties of endogenous opioids 
              Derived from large precursor protein preproopiomelanocortin 
(POMC), Preproenkephalin, preprodynorphin encoded by corresponding gene. 
              Each precursor is subject to complex clevages by trpsin like enzymes 
at sites designated by pairs of dibasic aminoacids to post translational 
modifications resulting in synthesis of multiple peptides, some of which are 
active. 
                 Most opioid share the common amino terminal sequence of Tyr – 
Gly – Gly- Phe- Met or Leu  followed by various C terminal extensions 
yielding peptides ranging from a few to many residues . 
a. Proenkephalin – It contains multiple copies of metenkephalin and single 
copy of leuenkepalin. They are present in areas of the central nervous system 
and are  related to the 
 a. Processing of pain information for example lamina 1 and 2 of spinal cord, 
spinal trigeminal nucleus and peraqueductal gray. 
b. To the modulation of motor control ( caudate nucleus and globus pallidus ) 
c. To the regulation of autonomic nervous system ( medulla oblongata) 
d. To neuroendocrinological functions ( median eminence) 
18 
 
b.Prodynorphin – It contains three peptides of differing lengths that begin 
with leuenkephalin sequence, Dynorphin-A, Dynorphin-B and Neoendorphin. 
They are distributed widely in neurons and lesser extent in the astrocytes 
throughout brain and spinal cord. 
c.Endorphin – β endorphin is a potent opioid agonist derived from cleavage of 
betalipotropin generated by proteolytic cleavage of POMC. POMC distribution 
is limited with in central nervous system , in the arcuate nucleus of the 
hypothalamus and nucleus tractus solitaries and also in the anterior and 
intermediate lobes of pituitary and pancreatic islet cells . 
d.Endomorphins– It is a recently identified peptide endomorphin 1 and 
endomorphin 2 they have an atypical structure and selective towards µ opioid 
receptor. 
e.Nociception peptides (orphanin FQ) – They are Present in the neurons of 
cortex , hippocampus , brainstem , hypothalamus, raphe nuclei and 
periaqueductal grey of the brain and are also present in the spinal cord
24
. 
B. OPIOID RECEPTORS 
Opioid systems are critical in the modulation of pain behavior and nociception. 
Opioid peptides and their receptors are expressed throughout the nociceptive 
neural circuit. Opioid receptors were pharmacologically and genitically 
identified over decades ago. Opioid receptors are targeted for treatment of pain 
thousands of years ago.  
19 
 
Subtypes of opioid receptor  
                         Mu -   , , least characterized 
receptor is opoid receptor like (ORL 1). All the receptors are G protein coupled 
and activate inhibitory G proteins. 
                          Opioid receptors are expressed in pain modulating descending 
pathway which include medulla, locus coeruleus and periaqueductal grey area. 
They are also expressed in limbic, midbrain and cortical structures. The 
activation of opioid receptors at these locations directly inhibit neurons which 
in turn inhibit spinal cord pain transmission. All four receptors are seven 
membrane spanning protein that couple to inhibitory G protein. After the 
activation of opioid receptor by endogenous or exogenous opioids the G α and 
G β ᵞ subunits dissociate from one another and acts on various intracellular 
effector pathway. When activated all  the four receptors cause reduction in 
calcium current that are sensitive to P/Q type ,N type and L type
25
. 
MEDIATORS OF PAIN 
                     Acute inflammation is a rapid host response that deliver 
leucocytes and plasma proteins, antibodies to site of tissue injury. Acute 
inflammation has three major components 
1. Alterations in vascular caliber that lead to an increase in blood flow 
2. Structural changes in the microvasculature that permit plasma proteins 
and leucocytes to leave the circulation  
20 
 
3. Emigration of the leucocytes from microcirculation and their activation 
to eliminate offending agent. 
General principles of Mediators of inflammation  
a.  Mediators are generated either from cells or from plasma proteins -The 
major cell that produce mediators of acute inflammation are platelets, 
neutrophils, monocytes/macrophages. Cell derived mediators are 
sequestered in intracellular granules and rapidly secreted by granule 
exocytosis in response to a stimulus. 
b. Active mediators produced in response to stimuli – The stimuli are the 
microbial products , substance released from necrotic cells and the 
proteins of the complement , kinin and coagulation systems. 
c. One mediator can stimulate the release of other mediators – cytokine 
and Tumor Necrosis Factor (TNF) act on endothelial cells to stimulate 
the production of another cytokine IL-1 and many chemokines. 
d. Once activated and released from the cell most of the mediators are 
short lived they quickly decay or inactivated by enzymes or scavenged 
or inhibited
26
. 
Mediators of inflammation are classified as follows 
1. Cell derived Mediators  
2. Plasma protein–derived mediators 
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I . CELL DERIVED MEDIATORS 
 
a. Vasoactive amines – Histamine and Serotonin  
 Histamine – It is a principal mediator of immediate transient phase of 
increased vascular permeability .They are stored as preformed 
molecules in cells and are the first mediators to be released during 
inflammation. The richest source of histamine is mast cells and are also 
found in blood basophils and platelets. Histamine is released from the 
mast cells by mast cell degranulation in response to  
1. Physical injury, trauma, cold or heat 
2. Binding of antibodies to mast cells  
3. Complement fragments called anaphylatoxins C3a and C5a  
4. Histamine releasing proteins derived from leucocytes 
5. Neuropeptides (substance P) 
6. Cytokine (IL-1,IL-8) 
Histamine cause immediate vasodilation of arterioles and increased 
permeability of venules. 
 Serotonin – It is present in platelets and neuroendocrine cells preformed 
vasoactive mediator  
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b. Arachidonic acid (AA) metabolite – Prostaglandins , leukotrienes and 
lipoxins  
                    When cells are activated by a stimuli like microbial products and 
various mediators of inflammation, membrane arachidonic acid is converted to 
prostaglandins and leukotrienes by action of various enzymes. Arachidonic 
acid is a 20-carbon polyunsaturated fatty acid derived from dietary sources or 
by conversion from the essential fatty acid linoleic acid and are esterified in 
membrane phospholipids. Mechanical, chemical, and physical stimuli or other 
mediators (C5a) release arachidonic acid from membrane phospholipids 
through the action of cellular phospholipase A2.  Arachidonic acid derived 
mediators, also called eicosanoids, are synthesized by two major classes of 
enzymes : 
                      1. Cyclooxygenases that generate prostaglandins  
                     2. Lipoxygenases that produce leukotrienes and lipoxins.  
Eicosanoids bind to G protein–coupled receptors on many cell types and can 
mediate the process of inflammation. 
 Prostaglandins (PGs) -They are produced by mast cells, macrophages, 
endothelial cells, and other cell types  involved in the vascular and 
systemic reactions of inflammation. They are produced by the actions of 
two cyclooxygenases, COX-1 and  COX-2. 
23 
 
Prostaglandins are divided based on structural features in to  PGD, PGE, 
PGF, PGG, and PGH and a subscript numeral (e.g., 1, 2), which indicates the 
number of double bonds in the compound. The most important PG in 
inflammation are PGE2, PGD2, PGF2α, PGI2 (prostacyclin), and TxA2 
(thromboxane).  
PGE2 – It is widely distributed  and  causes vasodilation and increases the 
permeability of post capillary venules. It makes skin hypersensitive to painful 
stimuli.  
PGD2 –It is a chemo attractant for neutrophils  
PGF2α –It Produce uterine contraction , bronchial smooth muscle contraction  
PGI2 – It Produce vasodilation , potent inhibitor of platelet aggregation .  
TXA2 – It is a potent platelet aggregating agent and vasoconstrictor and it is  
rapidly converted to inactive form TXB2. 
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FIGURE – 2  
GENERATION OF ARACHIDONIC ACID METABOLITES AND 
THEIR ROLES IN INFLAMMATION
26 
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 Leukotrienes – The lipoxygenase  enzyme is  responsible for the 
production of leukotrienes secreted  by leukocytes. There are three 
different lipoxygenases, 5-lipoxygenase is predominant  in neutrophils 
that converts arachidonic acid in to 5-hydroxyeicosatetraenoic acid and 
it is chemotactic for neutrophils and is the precursor of the leukotrienes. 
LTB4 - potent chemotactic agent and activator of neutrophils, causing 
aggregation and adhesion of the cells to venular endothelium, generation of 
Reactive oxygen species, and release of lysosomal enzymes.  
LTC4, LTD4, LTE4 - The cysteinyl containing leukotrienes cause 
vasoconstriction, bronchospasm  and increased vascular permeability. 
 Lipoxins  - They are also generated from arachidonic acid  by the 
lipoxygenase pathway, but unlike prostaglandins and leukotrienes, they 
are inhibitors of inflammation. The main action of lipoxin is to inhibit 
leucocyte recruitment and cellular component of inflammation. They 
inhibit neutrophil chemotaxis and adhesion to endothelium and they are 
endogenous negative regulators of leukotrienes and   thus produce 
resolution of inflammation. 
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C.Other mediators of inflammation  
 Platelet-Activating Factor (PAF) -   Phospholipid-derived mediator 
that causes platelet aggregation and have multiple inflammatory effects  
 Reactive Oxygen Species -Oxygen-derived free radicals released  from 
leukocytes after exposure to microbes, chemokines, and immune 
complexes.  
 Nitric Oxide (NO) –It is a factor released from endothelial cells that 
caused vasodilation and are called as endothelium-derived relaxing 
factor. NO is a soluble gas that is produced by macrophages and neurons 
in the brain.NO is synthesized from L- Arginine by the enzyme nitric 
oxide synthase (NOS). 
 Cytokines and Chemokines – cytokines are proteins produced by 
lymphocytes, macrophages and by endothelial, epithelial, and 
connective tissue cells. Cytokines involved in acute inflammation are 
IL-1, IL- 6, TNF. 
 Lysosomal Constituents of Leukocytes - Neutrophils and monocytes 
contain lysosomal granules, when released produce the inflammatory 
response. Neutrophils have two types of granules, the smaller specific 
granules contain lysozyme, collagenase, gelatinase, lactoferrin, 
plasminogen activator, histaminase, and alkaline phosphatase and the 
larger azurophil granules contain myeloperoxidase, bactericidal factors 
(lysozyme), acid hydrolases, elastase, cathepsin G, nonspecific 
collagenases and proteinase.  
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 Neuropeptides - They  are secreted from  sensory nerves and various 
leukocytes, and play an important  role in the initiation and propagation 
of an inflammatory response. Substance P and Neurokinin A belong to a 
family of tachykinin. Neuropeptides are produced in the central and 
peripheral nervous systems. Substance P has biologic functions like 
transmission of pain signals, regulation of blood pressure, stimulation of 
secretion by endocrine cells, and increasing vascular permeability. 
Sensory neurons also produce pro-inflammatory molecules like 
calcitonin-related gene product.  
II. PLASMA PROTEIN–DERIVED MEDIATORS 
A variety of inflammatory response are mediated by plasma proteins 
that belong to three interrelated systems: the complement, kinin, and clotting 
systems. 
a. Complement System - It consists of more than 20 proteins that function 
in both innate and adaptive immunity for defense against microbial 
pathogens. 
b. Coagulation and Kinin Systems – Inflammation and blood clotting are 
interwined with each promoting the other . Inflammation increases the 
production of several coagulation factors and makes the endothelial 
surface pro-thrombogenic, and inhibits anticoagulation and there by 
promoting clotting.  
c. Kinins – They are vasoactive peptides derived from plasma proteins 
called kininogens by action of protease , kallikriens . The active form of 
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factor XII, factor XIIa, converts plasma prekallikrien in to an active 
proteolytic form, kallikrien.  which cleaves  high molecular weight 
kininogen to bradykinin. Bradykinin increases vascular permeability and  
produce contraction of smooth muscle  and also dilation of blood vessels 
and produce pain when injected to skin.  The action of bradykinin is 
short-lived as it is quickly inactivated by an enzyme kininase
27,28,29,30
. 
SYSTEMIC RESPONSES TO PAIN          
Acute pain is associated with neuroendocrine stress response and it is 
proportional to pain intensity. Sympathetic activation increases the 
sympathetic tone and releases catecholamines from adrenal medulla. 
 Cardiovascular effects – Includes hypertension, tachycardia, 
myocardial irritability, increased systemic vascular resistance Pain can 
aggravate or precipitate myocardial ischemia due to increase in 
myocardial oxygen demand. 
 Respiratory effects – Increase in minute ventilation as there is increase 
in total body oxygen consumption and carbondioxide production. 
Prolonged bed rest or immobilization due pain produce change in 
pulmonary function. 
 Gastrointestinal and urinary effects – Increased sympathetic tone 
increases sphincter tone and decreases urinary and intestinal  motility . 
Hyper secretion of  gastric acid promote stress ulcer. Nausea, vomiting 
and constipation are common. 
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 Endocrine effects – Stress increases catabolic hormones and decreases 
anabolic hormones . Increase in cortisol with increase in renin 
angiotensin and antidiuretic hormone results in sodium and water 
retention . 
 Hematological effects – Stress increases platelet adhesiveness, reduced 
fibrinolysis and hypercoagulability . 
 General sense of well-being – Anxiety , sleep disturbance occurs31. 
MEASUREMENT OF PAIN  
                           Accurate assessment of acute pain is essential for the 
development of an effective pain management plan
32
. Patients self-report is a 
reliable indicator of pain , as pain is a subjective experience and it is the 
patients perception that is documented
32
. Pain is assessed as follows  
 At regular time intervals consistent with surgery type and severity 
of pain 
 With each new report of pain 
 At suitable interval after each analgesic intervention33 . 
 Pain assessment tools should be reliable for the patient population. Self -
reported measurement tools can be classified as 
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I. UNIDIMENSIONAL TOOLS   
a. Numeric rating scale (NRS) - It is a segmented numeric version of the 
visual analog scale (VAS) in which the patient selects a whole number 
(0–10 integers)  reflects the intensity of their pain . 
 
 
b. Visual analog scale (VAS) - It is a continuous scale comprised of a 
horizontal (HVAS) or vertical (VVAS) line  of  10 centimeters (100 
mm) in length. For pain intensity score of 0 is considered as “no 
pain”and score of 10 in 10 cm scale is considered as “pain as bad as it 
could be” or “worst imaginable pain”. Patient is  asked to place a line 
perpendicular to the VAS line at the point that represents their pain 
intensity. Using a ruler, the score is determined by measuring the 
distance on the 10-cm line. The results are interpreted as , no pain (0– 
0.4 cm), mild pain (0.5–4.4 cm), moderate pain (4.5–7.4 cm), and severe 
pain (7.5–10 cm)32,34.  
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c. Verbal rating scale (VRS) - It is the oldest and the simplest form of pain 
measurement tool . In clinical practice, four-descriptor verbal rating scale 
measuring pain is used with words none ,mild, moderate, and severe pain. The 
five- word scale consists of mild, discomforting, distressing, horrible and 
excruciating. 
d. Faces pain scale – revised (FPS-R) -  It is scored 0-10 or 0-5 . The face 
pointed to left shows no pain and faces show more and more pain from left to 
right. the patient is asked to point the face how much they are hurt
35
 . 
e. Wong-Baker Faces pain rating scale - It is an ordinal out- come measure 
with limited number of categorical responses. This consists of six facial 
expressions and it is explained to the patients that each face is for a person who 
feels happy, face 0 is  very happy doesn’t hurt at all., face 1 hurts just a little 
bit, face 2 hurts a little more , face 4  hurts a whole more , face 5 is hurts as 
much as you can imagine 
35,36,37
. 
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II. Multidimentional tools  
a. Mcgill pain questionnaire (MPQ) - Multidimensional pain 
questionnaire to measure the sensory, affective and evaluative aspects of 
pain and pain intensity in adults with chronic pain. 
b. Short- form Mcgill pain questionnaire (SF-MPQ) - It is a shorter 
version of the MPQ and it is a multidimensional measure of perceived 
pain in adults with chronic pain. 
c. Quantitative sensory testing (QST) - Non- invasive form of 
somatosensory testing that provides information of the afferent pain 
pathway from receptor to brain
32,33
.  
 MANAGEMENT OF POST OPERATIVE PAIN 
Pain management are targeted at the preoperative period. Preemptive 
analgesia involves preoperative administration of analgesics that helps to 
reduce the consequences of afferent nociceptive neurotransmission during 
surgery and thereby decreasing postoperative pain. Preventive analgesia 
involves prevention of central sensitization by blocking the neural transmission 
of all noxious perioperative stimuli arising from the time of incision to till 
wound healing.  
Intraoperative approaches include neuraxial analgesia, continuous local 
anesthetic wound infusion, intravenous acetaminophen and intravenous 
ketamine. Pain management approaches during the postoperative period is the 
traditional pharmacological approach which include oral or intravenous 
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administration of opioids and oral administration of acetaminophen or 
NSAID
38
. 
a. Pharmacological management of pain  
 Opioid analgesics  
 Non-opioid analgesics non-steroidal anti-inflammatory drugs 
b. Non - pharmacological management of pain 
 Psychological interventions 
 Physical therapy 
 Acupuncture 
 Electrical stimulation 
 
A. PHARMACOLOGICAL MANAGEMENT OF PAIN  
a. OPIOID ANALGESICS  
     There are three types of opioid receptors are MOR ( mu- μ), DOR (delta -δ) 
and KOR (kappa- κ). Based on their methods of stimulation, opioids can be di-
vided into full agonists, partial agonist, agonist-antagonist. Full agonist is 
characterised by relative selectivity for μ receptors, similar to morphine, partial 
agonists shows partial agonism mainly for μ receptors, and opioids of mixed 
agonistic-antagonistic properties interact with more than one class of receptors 
and  therefore it can act as agonists for one receptor and as antagonists for the 
other. The most important opioids used in acute pain management include 
morphine, oxycodone, fentanyl, nalbuphine, buprenorphine and tramadol. 
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Opioids commonly used for pharmacological relief of moderate to severe post-
operative pain. Their doses should be tailored individually depending on the 
pain evaluation scores and their possible adverse side effects.  
Mechanism of opioid induced analgesia  
The analgesic actions of opiates after systemic delivery has actions in the brain, 
spinal cord, and in the periphery. 
Supra spinal Actions - The microinjection of opiates through microinjection 
cannulae targeted at specific brain sites like mesencephalic periaqueductal gray 
(PAG) matter   has shown that opiate agonists  act on MOR, block pain 
behavior and  the analgesic effects are reversible by naloxone.  
Spinal Opiate Action - A local action of opiates in the spinal cord will  
depress the discharge of spinal dorsal horn neurons evoked by small  but not 
large  afferent nerve fibers. Spinal opiates reduce the release of primary 
afferent peptide transmitters such as substance P  in the small afferents . The 
presynaptic action  prevent the opening of voltage-sensitive Ca
2+
 channels 
preventing transmitter release. Opiates in postsynaptic action  block the 
excitation of dorsal horn neurons directly  by glutamate. The joint action of 
spinal opiates to reduce the release of excitatory neurotransmitters from C 
fibers and to decrease the excitability of dorsal horn neurons  account for the 
powerful and selective effect of opiates on spinal nociceptive processing. 
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Peripheral Action - Direct application of opiates to a peripheral nerve  
produce a local anesthetic-like action at high concentrations and are  not 
naloxone reversible
39
. 
 Morphine -It is a natural opium alkaloids obtained from the unripe seed 
capsules of the poppy plant, Papaver somniferum. Opioids are modestly 
absorbed from the gastrointestinal tract; absorption through the rectal 
mucosa is adequate. Lipophilic opioids are absorbed readily through the 
nasal or buccal mucosa and those with the greatest lipid solubility are 
absorbed transdermally. It is widely used for spinal delivery to produce 
analgesia though a spinal action. One-third of morphine in the plasma is 
protein-bound after a therapeutic dose. Morphine does not persist in 
tissues, and 24 hours after the last dose, tissue concentrations are low 
and are metabolized by glucuronide conjugation  and  two major 
metabolites formed are morphine-6-glucuronide and morphine-3-
glucuronide. It is eliminated by glomerular filtration as morphine-3-
glucuronide
39
. Morphine is used with caution in individuals with 
advanced kidney failure because of the possible accumulation of its 
active metabolite (morphine-6-glucuronide), which can cause 
respiratory failure.  
 Oxycodone -The drug is available in intravenous, oral and other forms. 
The combination of this drug in its intravenous controlled-release form 
acts immediately. Oxycodone has two-phase absorption model,  initial 
rapid absorption the first phase of action  occurs after approximately 40 
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min this is followed by slow drug release over 12 hours at the constant 
serum concentration of the analgesic that is being maintained. Due to 
this action, oxycodone can be included in the group of potent drugs used 
for post-operative pain relief. Oxycodone administered orally is roughly 
twice as strong as oral morphine but the intravenous route of opioid 
administration during the first post-operative phase, with the possibility 
of changing to oral administration, is ideal for severe post-operative pain 
management. Oxycodone and other opioids of similar analgesic action 
are commonly used for the therapy of moderate-to-severe pain when 
there is fear of complications associated with the supply of NSAIDs. 
 Fentanyl - It is a synthetic opioid. Its action is 50– 80 times greater than 
that of morphine.  It has quick onset of action 10 sec after intravenous 
administration. The time of action after the administration of 0.1 mg is 
1–1.5 hours. Fentanyl is recommended when rapid, efficacious analgesia 
is required .Owing to its short action, it should be used in continuous 
infusions. Fentanyl can be used in patients with impaired renal functions 
as it is metabolised into inactive metabolites in the liver. 
 Tramadol - It is one of the weak agonist opioid receptors . It is a 
synthetic analogue of codeine that acts centrally. It can be used 
intravenously and parentrally for moderate and severe pain. The  
comparison of analgesic potency of tramadol  with other opioids is as 
follows tramadol:nalbuphine 5:1; tramadol:fentanyl 979:1; 
tramadol:oxycodone 8:1, tramadol:morphine 10:1. 
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           The increased analgesic action is due to inhibition of noradrenaline 
reuptake in neurons and an increase in serotonin release. In individuals treated 
with tramadol there is a risk of seizure in recommended doses. This risk  
increases if the recommended daily dose of 400 mg is exceeded and in patients 
with a history of seizures or those who are taking simultaneously serotonin and 
noradrenaline reuptake inhibitors, tricyclic antidepressants, anti-psychotic 
drugs or other agents that reduce the seizure threshold. Tramadol’s capacity to 
produce respiratory depression is minimal therefore it is used for labour 
analgesia, pain relief in children, short-term and day case surgeries and after 
trauma. Tramadol is highly efficacious when combined with metamizole for 
pain management in renal or biliary colic.  
 Codeine - It is a natural opioid and one of the major opium alkaloids. It 
shows low affinity to opioid receptors. Its analgesic action is provided 
by its active metabolite morphine. The conversion of codeine to 
morphine is mediated by  CYP2D6. The doses for relieving pain are 30–
60 mg administered every 4 h to maximum daily dose of 240 mg .  
A half-synthetic derivative of codeine is dihydrocodeine with 
similar pharmacological properties. Its bioavailability after oral 
administration is about 20% and it is metabolised in the liver by the 
cytochrome CYP2D6 into dihydromorphine and others.  
 Buprenorphine - It is a partial agonist and it is similar to opioids of 
mixed agonistic-antagonistic properties, such as nalbuphine or 
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butorphanol. Agonist -antagonists have limited use for chronic pain 
owing to their dose-dependent, psychosis-mimetic action. Their use in 
patients  addicted to morphine or other full MOR agonists can cause 
withdrawal owing to their antagonistic effects on MOR. The dose of 5–
15 μg kg of parenteral buprenorphine provides analgesia comparable 
with that of intravenous  morphine for up to 13 hours. Sublingual 
buprenorphine is recommended for maintaining post-operative analgesia 
It is useful as post-operative analgesic in patients who had been abused 
with opioids. 
Transdermal buprenorphine is very effective due to its high 
solubility in fat. It is mostly recommended for chronic pain, but  
numerous reports from various European countries recommends  its  
usefulness  for acute pain. Transdermal buprenorphine is available in the 
doses of 35, 52.5 and 70 μg h-1 and the effect lasts for 3 days. The onset 
of action is after 12–24 hours.  Buprenorphine is useful and 
recommended in patients with kidney failure.  It is used in the elderly as 
it is long acting. Buprenorphine prevents hyperalgesia and hence can be 
used in patients with chronic pain who undergo surgeries or after 
trauma. 
Drugs such as opioids, sedatives, hypnotics, antidepressants and 
others can induce or inhibit the isoenzyme of cytochrome P450 which 
may increase the central effects of buprenorphine. Great caution should 
be exercised when benzodiazepines are used simultaneously as this 
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combination can lead to intensified sedation, respiratory depression or 
even death 
 Nalbuphine - It is a KOR agonist and MOR antagonist. As it is a MOR 
antagonist it prevents side effects associated with MOR stimulation like 
respiratory depression, addiction, euphoria, bradycardia, pruritus, 
immunosuppression, nausea and vomiting, impaired peristalsis, 
weakened muscular tone of the urinary bladder 
Nalbuphine is metabolised in the liver and excreted through the 
kidneys so great caution should be taken when using the drug in patients 
with failure of these organs.  10 mg of nalbuphine can cause respiratory 
depression similar to 10 mg of morphine but unlike with morphine  
nalbuphine shows the upper limit effect. The upper limit of respiratory 
depression occurs at a dose of 30 mg, and the upper limit analgesic ef-
fect is observed at 50 mg. In adults, intravenous dose used is  0.1–0.3 
mg kg , without exceeding 20 mg. The maximum action is observed 2–3 
minutes after intravenous administration and the dose can be repeated 
after 3–6 hours39,40 . 
WHO Analgesic Ladder 
For mild pain – Non opioids ( eg. NSAIDS, paracetamol) 
For   moderate    pain –   weak   opioids (eg. Codeine) with or 
without non-opioids. 
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For severe pain – strong opioids (eg.morphine) with   or without 
non-opoids
18
. 
 Opioid associated complications 
1. Tolerance and dependence – Repeated doses of opioids have diminishing 
analgesic effect, increases dose requirement needed to achieve analgesia. 
Physical dependence is characterized by with drawl syndrome after 
discontinuation of drug. 
2. Addiction – it is characterized by inability to abstain consistently, 
impairment in behavioural control, craving, dysfunctional emotional response. 
3. Respiratory system – Dose dependent respiratory depression with 
decreased minute ventilation via decreased respiratory rate is enhanced by CNS 
depressants, renal insufficiency and respiratory acidosis. Tolerance develops 
with repeated dosing and can be treated with naloxone. 
 4. Central nervous system - Sedation which is dose-dependent and may 
precede analgesia. Enhanced by CNS depressants and treated with naloxone. 
5. GI Side Effects – Nausea vomiting are produced and are treated  with 
serotonin and dopamine antagonists. It can produce decreased intestinal 
motility and constipation. Tolerance does not develop with repeated dosing and 
it also produce biliary spasm. 
6. Pruritus – produced not due to histamine release and it is difficult to treat 
without reversing analgesic effects with opioid antagonists 
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7. Less Common Adverse Effects 
a. Urinary retention - Treated with naloxone and methylnaltrexone 
b. Confusion and mental status changes - Common in elderly patients 
c. Bradycardia - Exacerbated by concurrent use of beta-blockers and calcium-
channel blockers 
d. Muscle rigidity - Seen with high doses and often requires neuromuscular 
blockade
41,42
. 
Contraindications and caution  
1. Pure agonists with weak partial agonists – Pentazocine ,is a partial agonist is 
given with full agonist morphine , analgesia is diminished or there will be a 
state of with drawl so this combination should be avoided. 
2. Head injury patients – respiratory depression produce  carbondioxide 
retention which results in cerebral vasodilation, when there elevated 
intracranial tension it may lead to lethal alterations in  brain function.   
3. Pregnancy – Foetus become physically dependent in utero and manifest 
with-drawl symptoms in early postpartum period when given during 
pregnancy. 
4. Patients with impaired pulmonary function – Depressant property leads to 
acute respiratory failure. 
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5. Patients with impaired hepatic or renal function – In renal impairment half-
life is prolonged as they are metabolized in the liver , their use in prehepatic 
coma is questionable. 
6. Patients with Endocrine disease – Patients with addison’s disease and 
myxedema have prolonged and exaggerated response
41
. 
b. NON-OPIOID ANALGESICS NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS (NSAIDS)  
This group of drugs includes COX-1 and COX-2 inhibitors. The 
efficacy of these two types of COX inhibitors after surgeries accompanied by 
mild and moderate pain is comparable. In cases of classic NSAIDs used in 
patients at risk of gastrointestinal side effects, it is important to add a proton 
pump inhibitor. 
Mechanism of action of NSAID 
The main mechanism of action is inhibition of the enzyme 
cyclooxygenase which is responsible for the synthesis of prostaglandins and 
related autacoids like thromboxane. Prostaglandins are involved in the various 
physiological and pathological process of pain, fever and inflammation. 
NSAID has common action of analgesic, antipyretic and anti-inflammatory 
action due to inhibition of prostaglandins.  
           There are two types of cyclooxygenase enzyme cyclooxygenase-
1(COX-1) and cyclooxygenase-2 (COX-2) responsible for physiological and 
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pathological process respectively. COX-1 are present in platelets in blood and 
are responsible for tissue homeostasis and physiological process. COX-2 
enzyme are present in the inflammatory cells and are activated by 
inflammatory cytokines Interleukin -1 (IL-1) and Tumour necrosis factor alpha 
(TNFα) and cause production of prostaglandins producing fever and 
pathological process. 
                            The commonly used NSAID inhibit both the enzymes 
producing anti- inflammatory action. Recently selective COX-2 inhibitors have 
anti- inflammatory action without side effects produced due to COX 1 
inhibition.   
 Metamizole - Metamizole has been available worldwide since 1922 and 
it is an analgesic, antipyretic. It is a therapeutic agent from the group of 
pyrazoline derivatives. They are administered as a prodrug orally, 
rectally, intramuscularly or intravenously. The absorption is quick after 
oral administration and  bioavailability is 85% and time till maximum 
plasma concentration (Tmax) of 1.2–2.0 h.  After intravenous 
administration its analgesic effect begins within 30 minutes  and last for 
approximately four hours. Metamizole is hydrolysed to active 
metabolites 4-methyl-amino-antipyrine (4-MAA) and aminoantipyrine 
(AA) and are excreted via the kidneys. The half-life is 2.5–3.5 h. In 
cases of severe toxicity or overdose it can be removed from the blood by 
hemodialysis.  
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The exact mechanism of its action is unknown and the findings 
from animal studies reveal that metamizole inhibits cyclooxygenase 
(COX) in peripheral tissues as well as the central nervous system. In the 
case of classic NSAIDs, COX activity is blocked by competing with 
arachidonic acid for the COX-binding site but in contrast, metamizole 
does not attach to this binding site but it inhibits the release from other 
binding places of free radicals, which are necessary to initiate COX-
mediated arachidonic acid metabolism.  
It has been revealed from  a recently published meta-analysis  that 
metamizole is an effective agent for alleviating post-operative pain.  
Indirect comparative studies  had shown that  500 mg of metamizole 
was as effective as 400 mg of ibuprofen and more effective than 1000 
mg of paracetamol. Contrary to NSAIDs, metamizole has low risk of 
gastrointestinal complications. Metamizole dilates the vascular smooth 
muscle and it can also reduce arterial pressure, especially when  rapid 
intravenous administration is given. No adverse effects of metamizole 
on the cardiovascular system or kidneys were seen.  Some of the 
contraindications for metamizole are allergies to metamizole and 
NSAIDs, severe arterial hypotension, hypovolaemia or shock, acute 
intermittent porphyria, glucose-6-phosphate dehydrogenase deficiency
40
. 
 Paracetamol (acetaminophen)- It is the most popular and most 
commonly used antipyretic and analgesic worldwide because of its low 
risk of adverse reactions and with proven analgesic efficacy. There are a 
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number of hypotheses regarding the central effects of paracetamol that 
could explain its analgesic efficacy. According to hypotheses regarding 
the central effects of paracetamol in analgesic activity, it inhibits the 
central activity of COX-2 and isoform of cyclooxygenase, COX-3. 
Warner and colleagues  described two COX isoenzymes  partial COX-1 
(pCOX-1) and COX 3,  predominantly seen  within the human cerebral 
cortex and heart. It is believed that COX-3 is encoded by the same gene 
that encodes COX-2 but differs in its molecular characteristics. COX-3 
is a variant of COX-2 , highly susceptible to paracetamol induced 
inhibition. Paracetamol also affect the antinociceptive serotonergic 
system thereby stimulating the activity of the descending serotonergic 
pathways (5-HT). The above hypothesis was supported by the finding 
the clinical trial that the combined use of paracetamol and  antiemetic 
drugs like 5-HT3 antagonists granisetron or tropisetron inhibited 
analgesic action of paracetamol.  
Paracetamol is metabolised predominantly in the liver, and 
therefore caution should be taken in patients with active liver disease, 
long-term alcohol abusers and those with limited glutathione stores. 
Hepatotoxicity is caused by oxidised N-acetyl-p-benzoquinone imine 
(NAPQI) metabolite. It constitutes only 5% of paracetamol metabolites 
and is usually bound by glutathione. If the glutathione stores were 
depleted after overdose or were deficient, NAPQI binds liver proteins, 
causing necrosis of the central part of the hepatic lobules and it develops 
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over a period of 4 to 14 days. The cause of depleted glutathione levels 
include starvation, malnutrition, HIV infection and regular alcohol 
consumption. Paracetamol is an useful component of multimodal 
analgesia, which can be used in combinations with various opioids like 
codeine, tramadol and morphine
40,43
.  
 Ibuprofen – This is a propionic acid derivative . The oral absorption is 
rapid, 99% protein bound and the  t1/2 is 2hrs. Excretion is rapid and 
complete and 90% is excreted as carboxylated and hydroxylated 
metabolite with or without glucuronide conjugation. It is a commonly 
used NSAID.   
 Diclofenac - It is a phenylacetic acid derivative. It is a nonselective 
cycloxygenase inhibitors. It has analgesic, anti-inflammatory and 
antipyretic action. Oral absorption is rapid and complete with extensive 
first pass metabolism with bioavailabilty of 50%. 99% bound to plasma 
proteins with t1/2 of 1-2hrs. It is metabolized by CYP2C in the liver and 
excreted in urine and bile.It is useful for postoperative pain and can be 
used by parentral route, it can also be used for rheumatoid arthritis, 
osteoarthritis , tendonitis , bursitis , dysmenorrhoea. 
 Ketorolac – It is a nonspecific cyclooxygenase inhibitor. It is a 
parenterally  administered NSAID that provides analgesia by inhibiting 
prostaglandin synthesis. It is indicated for short term management of 
pain and useful for pain in immediate post - operative period .It does not 
cross the blood brain barrier it is a peripherally acting drug used 
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alternative to opioids for post- operative pain and it does not cause 
sedation or respiratory depression  or nausea or vomiting. Dosage given 
is 60mg intramuscularly or 30mg intravenous loading dose with 
maintenance dose of 15-30mg every 6hours
44
. 
 Lornoxicam- It is a member of the oxicam group of nonsteroidal anti-
inflammatory drugs (NSAIDs), producing analgesic and antipyretic 
effects through the non-selective inhibition of cyclo-oxygenase-1 and -
2. Besides its inhibitory effect on COX1 and COX-2 peripheral 
receptors, is also increases  endogenous dinorphin and beta-endorphin 
levels promoting central analgesic and anti-inflammatory effects. 
Recently, lornoxicam has been introduced in Indian market in oral, 
intravenous and intramuscular formulations. Lornoxicam is completely 
absorbed after oral administration, reaching peak plasma concentrations 
of 280 mg/L within 2.5 hours after a 4 mg dose. After intramuscular 
injection maximum plasma concentrations are achieved after 
approximately 20-25 minutes. Lornoxicam is extensively metabolised 
in liver by cytochrome P4502DC9 to inactive metabolite 5’-hydroxy-
lornoxicam. The mean elimination halflife is 3 to 4 hours
45
.   
 Coxibs – COX-2 selective NSAID - It has an action similar to 
conventional NSAIDs with the difference in selective inhibition of 
COX-2 . The advantages are it has less gastrointestinal side effects , do 
not precipitate bronchial asthma and has no antiplatelet action. The 
disadvantages are they increase the incidence of cardiovascular 
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thrombotic episodes and renal toxicity. Commonly used coxibs are 
celecoxib, rofecoxib, valdecoxib, parecoxib , lumiracoxib, etoricoxib. 
Parecoxib is the only coxib available as injection and effective 
analgesic for pre and postoperative period
43
. 
Adverse effects of the NSAIDs: 
1. Central nervous system: Headaches, tinnitus, and dizziness. 
2. Cardiovascular: Fluid retention, hypertension, edema, and rarely, 
myocardial infarction, and congestive heart failure. 
3. Gastrointestinal: Abdominal pain, nausea, vomiting and rarely ulcers or 
bleeding. 
4. Hepatic: Abnormal liver function tests and rarely liver failure  
5. Hematologic: Rare thrombocytopenia, neutropenia, aplastic anemia. 
6. Pulmonary: Asthma. 
7. Skin: Rashes, pruritus. 
8. Renal: Renal insufficiency, renal failure, hyperkalemia, and proteinuria
46
. 
ADVANCES IN PHARMACOLOGICAL MANAGEMENT OF ACUTE 
POSTOPERATIVE PAIN  
New opioids and opioid formulations with unique pharmacodynamics 
profile, with analgesic effect and minimal adverse effects are being developed. 
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 Tapentadol- It is a centrally acting mu opioid receptor agonist and 
norepinephrine reuptake inhibitor approved for treatment of moderate to 
severe pain. 
 Patient controlled analgesia (PCA) – It is safe and effective method of 
postoperative pain management.  Intravenous opioids and pain 
controlled epidural analgesia with Opioids or local anasthetics are used 
in PCA. 
 Patient controlled regional anesthesia (PCRA) – local anasthetics are 
administered in to surgical incision ,intra articular tissue ,or perineural 
site . 
 Patient controlled intranasal ketorolac tromethamine –  It was 
approved in 2010 for short term (5days)  management of moderate to 
moderately severe pain in adults . 
 Patient controlled Fentanyl iontophoretic transdermal system 
(PCTA -fentanyl ITS) It is an alternative to intravenous PCA. It is used 
for acute postoperative pain in adults . The advantage is lowers the risk 
of intravenous PCA related complications like mechanical pump errors, 
intravenous catheter infection and operating errors. 
 Patient controlled sublingual sufentanil system (PCSA) – It is under 
development. It is designed in such a way to overcome the disadvantage 
of intravenous PCA like infections of indwelling intravenous catheter 
and human programming errors
38
. 
  
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OTHER DRUGS  USED FOR PAIN MANAGEMENT  
 Antiepileptics – Gabapentin, Lamotrigine, Tiagabine, Phenytoin, 
Carbamazepine, Valproate, Oxcarbazepine, Clonazepam, Topiramate. 
 Antidepressants – Amitriptyline, Nortriptyline, Desipramine, 
Citalopram Bupropion, Doxepine, Escitalopram Fluoxetine, Sertraline, 
Trazodone, venlafaxine. 
 Neuroleptics – Fluphenazine , Haloperidol ,Chlorpromazine, 
Perphenazine. 
 Corticosteroids – Hydrocortisone, Prednisone, Prednisolone, Methyl 
Prednisolone, Triamcinolone, Betamethasone , Dexamethasone . 
 Systemic local anasthetics – Lidocaine, Procaine and Chloroprocaine 
most commonly used agents given as slow bolus or continuous infusion. 
 Alpha2 adrenergic agonists – clonidine produce activation of 
descending inhibitory pathways in dorsal horn
47,48
. 
B. NON – PHARMACOLOGICAL MANAGEMENT OF PAIN  
1. Psychological interventions – employed by psychiatrist and they 
include cognitive therapy ,behavioral therapy, relaxation technique and 
hypnosis. 
2. Physical therapy – Heat and cold provides relief  of pain by alleviating 
muscle spasm. Heat increases blood flow and cold vasoconstricts and 
reduce tissue edema. Superficial heating modalities are hotpacks, 
paraffin, hydrotherapy and deep heat application include ultrasound, 
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shortwave and microwave diathermy . For cold, cold packs,  
vapocoolant sprays and ice massage are used. 
3. Acupuncture – It is a technique involves insertion of needles in to 
defined points. Studies suggest that acupuncture stimulates the release  
of endogenous opioids and its effects are antagonized by naloxone. 
4. Electrical stimulation – it can stimulate the nervous system and can 
produce analgesia in patients with acute and chronic pain. Current is 
applied transcutaneously, epidurally or by electrodes implanted in to 
central nervous system. 
 Transcutaneous electric nerve stimulation (TENS) – produce 
analgesia by stimulating large afferent fibers. It has a role for 
patients with mild to moderate acute pain.  In conventional TENS 
electrodes are placed in the same dermatome as the pain and 
stimulated by direct current periodically .A current of 10-30mA  
with pulse width of 50-80µs is applied at frequency of 80-100Hz. 
Patients refractory to conventional TENS respond to low 
frequency TENS and it is partly reversed by naloxone. 
 Spinal cord stimulation (SCS) – Also called as dorsal column 
stimulation as it was thought to produce analgesia by directly 
stimulating large Aβ fibers in the dorsal columns of spinal cord. 
The proposed mechanism is activation of descending modulating 
systems and inhibition of sympathetic out flow. 
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 Intra cerebral stimulation – Deep brain stimulation can be used 
for intractable cancer pain and also for neuropathic pain. 
Electrodes are implanted in to the periventricular and 
periaqueductal gray areas for nociceptive pain  and for 
neuropathic pain placed in the specific sensory thalamic 
nuclei
47,48
.   
MASTOIDECTOMY 
The primary goal in surgical management of chronic otitis media with 
cholesteatoma is creation of a dry safe ear through removal of disease and the 
alteration of anatomy to prevent the recurrence
49
.  
TYPES OF MASTOIDECTOMY  
1. Cortical mastoidectomy or simple mastoidectomy or schwatz 
mastoidectomy – this was developed for the management of acute 
suppurative otitis media. It is a procedure that involves complete 
exenteration of all accessible mastoid air cells maintaining the 
integrity of post canal wall , middle ear structures and tympanic 
membrane inorder to have normal ear anatomically and 
physiologically. 
 Indications   
a. Treatment of suppurative mastoiditis 
b. Masked mastoiditis 
c. Secretory otitis media in resistant cases 
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d. Chronic all discharging ear with central perforation 
e. To expose mastoid segment of facial nerve 
f. Exposure of mastoid region in canal wall up tympanoplasty 
g. Saccus decompression surgery 
h. Translabyrinthine operations 
i. Retro labyrinthine approaches to vestibular nerve 
j. Exposure of sigmoid sinus 
k. Exposure of otic capsule for cochlear implant  
 Procedure – After infiltration with 1% xylocaine with adrenaline post 
auricular incision from pinna to mastoid tip is made, superficial fascia 
,muscles and periosteum are incised and separated. Mac Ewens triangle 
identified mastoid cortex and all matoid air cells are removed 
systematically under microscope with drill. Cavity edges saucerised and 
wound closed with interrupted sutures and drain. External auditory 
meatus is packed with cotton wick soaked in antibiotic ointment
50
 . 
2.Canal wall up tympanoplasty (closed tympanoplasty) – It is an 
operation performed to remove disease from the mastoid antrum , air 
cell system, aditus-ad- antrum and the middle ear through facial recess 
(posterior tympanotomy) with preservation of an intact posterior bony 
external auditory canal without disturbing the middle ear contents. 
 Indications  
a. Cholesteatoma in children and patients with highly pneumatised 
mastoids. 
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b. Minor epitympanic, mesotympanic cholesteatoma 
c. Cochlear implants 
d. Facial nerve decompression  
 Procedure – Simple matoidectomy is done, epitympanotomy and 
posterior tympanotomy done , middle ear is examined by elevating 
tympanomeatal flap. Cholesteatoma removed from the middle ear, attic 
and mastoid bone. 
3.Canal wall down procedure (open cavity matoidectomy) - the objective is 
to clear the disease and to make the attic, aditus-ad-antrum , mastoid and 
external auditory meatus in to single cavity with wide meatoplasty ,preserving 
hearing and establishment if drainage . 
 Indications : 
a. Cholesteatoma in mastoid 
b. Large epitympanic erosions 
c. Recurrence after closed technique 
d. Bilateral cholesteatoma 
e. Only hearing ear 
f. Large labyrinthine fistula 
g. Severe sensory neural deafness 
h. Benign tumours involving the middle ear 
i. Malignant tumours of external auditory canal 
 Procedure – simple mastoidectomy is the initial step . Bridge removed 
under magnification , anterior buttress is removed , facial ridge lowered 
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up to the floor of external auditory canal. Cavity is saucerised and wide 
meatoplaty done and wound closed in layers
50,51
 . 
5. Modified radical mastoidectomty (Bondy) – in this procedure the 
posterior canal wall is removed and the articulation between the ossicles 
are not touched. 
 Indications:  
a. Cholesteatoma  
b. Post canal wall cannot be reconstructed 
c. Nonfunctioning Eustachian tube 
d. Poor patient compliance 
e. Severe ontological or CNS complications 
 Procedure – same procedure as open cavity technique and the ossicular 
chain is not disturbed, conchal cartilage used as a support to prevent 
recurrence of retraction of tympanic membrane
50,52,53,54
. 
5.Radical mastoidectomy – Objective is to clear the disease and to make  
middle ear , attic , aditus-ad-antrum , mastoid cavity and external auditory 
meatus in to one single cavity draining through the external auditory canal. 
All the ossicles  in the middle ear and tympanic membrane are removed 
except foot plate of the stapes. Eustachian tube orifice is plugged with 
muscle or cortical bone. 
 Indications:  
a. Cholesteatoma with intracranial complications 
b. Blind sac closure after glomus tumour excision50. 
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6.Tympanoplasty – it is a procedure done to remove disease from middle ear , 
reconstruct hearing mechanism ( ossiculoplasty )  with or without repair of 
tympanic membrane. Usually tympanoplasty is combined with mastoidectomy. 
 
 Prerequisite for Tympanoplasty  
a. Adequate cochlear reserve must be present 
b. Eustachian tube function should be normal 
 Types of tympanoplasty (Wullstein) 
Type 1- reconstruction of tympanic membrane, ossicular chain is intact and 
mobile. 
Type 2- long process of incus is absent , remnant of incus is shaped and 
p0laced between handle of malleus and head of stapes 
Type 3- malleus and incus are absent , graft is placwd over the ontact head of 
the stapes ( columella effect / myringostapediopexy) 
Type 4- round window ( baffle effect ) – All the ossicles are absent  except 
mobile stapes foot plate . tympanic reconstruction is done by placing the graft 
over the promontory. 
Type 5 – fenestration –  All the ossicles are absent  and foot plate of stapes is 
fixed an opening is made in the bony lateral semicircular canal. 
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Type 6 – sonoinversion – round window is  exposed to sound waves and graft 
placed over the oval window
50,52,54
. 
ANESTHESIA FOR MASTOIDECTOMY  
                 Local anesthesia is preferred  by many surgeons for middle ear 
surgery . The advantages of local anesthesia are bleeding is less, presence of 
postoperative analgesia, mobilization of patient in short time, cost effective, 
reduced aspiration risk with normal cough reflex. Hearing can be tested during 
surgery and possibility of undergoing iatrogenic facial nerve weakness can also 
be evaluated.one hour before surgery preanasthetic medications like injection 
pentazocine, promethazine and atropine are given intramuscularly. Local 
anesthesia is given using 2% lignocaine with 1:10000 epinephrine for 
infiltration. Good patient selection is an important factor for the success of 
local anesthesia
55
.  
LORNOXICAM 
Introduction - It belongs to Enolic acid oxicam group. Lornoxicam is a 
congener of tenoxicam, new nonsteroidal anti-inflammatory drug. It decreases 
prostaglandin synthesis by inhibiting cyclooxygenase. It has strong analgesic, 
antipyretic and anti-inflammatory effects. Its analgesic property is comparable 
to opioids. Lornoxicam has a short elimination half-life of 3–5 h when 
compared to other drugs that belong to oxicam group. Lornocicam also hass 
rapid onset of action when compared to other oxicam groups
56,57
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Chemical structure - Chemically it is a 4-hydroxycarboxamide [6-chloro-4-
hydroxy-2-methyl-N-2-pyridyl-5H-thieno(2,3-e)-[1,2]-thiazine-2-carboxamide-
1,1- dioxide]. 
Mechanism of action -  Lornoxicam (chlortenoxicam) inhibits prostaglandin 
(PG) synthesis via inhibition of cyclooxygenase both COX-1 and COX-2 and it 
does not inhibit 5-lipoxygenase. Lornoxicam also inhibits polymorphonuclear 
(PMN) leukocyte migration, inhibits the release of superoxide from human 
PMN-leukocytes, inhibits the release of platelet derived growth factor (PDGF) 
from human platelets and stimulates the synthesis of proteoglycans in cartilage 
in tissue culture.  
Besides its inhibitory effect on the peripheral receptors of COX1 and 
COX-2 Lornoxicam also increases endogenous dinorphin and beta-endorphin 
levels promoting central analgesic and anti-inflammatory effects.  
Intravenous lonoxicam (8mg) has been shown to be as effective as 
morphine (20mg), pethidine (50mg) and tramadol (50mg) in the treatment of 
postoperative pain.  
 Pharmacokinetic properties - Lornoxicam is completely absorbed after oral 
administration. After a 4mg oral dose   peak plasma concentrations of 280 
mg/L is reached  within 2.5 hours. Studies have shown that the area  under the 
serum drug concentration-time curve (AUC) is proportional following 
lornoxicam doses between 2 to 6mg given twice daily for 2 weeks in healthy 
young volunteers.  Cmax and AUC of lornoxicam indicated drug accumulation 
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upon repeated administration.  Intra-gastric food delays and reduces the 
absorption of lornoxicam.  
After intramuscular injection of lornoxicam maximum plasma 
concentrations are achieved approximately after 20-25 minutes. The 
bioavailability after intramuscular injection is 97 percent. The plasma protein 
binding is 99 per cent and the apparent volume of distribution of lornoxicam is 
low (0.3L/Kg). It is extensively metabolised in liver by cytochrome P4502DC9 
in to inactive metabolite 5’-hydroxy-lornoxicam.  It has been found that 
approximately 51 percent drug is excreted in faeces and 42 percent via kidneys 
as inactive substance. The mean elimination half life of lornoxicam is 3 to 4 
hours. The drug has been found to be safe in elderly patients and in  patients 
with impaired renal function and  hepatic functions
56,57,58
. 
Therapeutic uses  
a. Analgesia - It produce dose related analgesia in acute and chronic pain .It is 
useful in the treatment of postoperative pain and other acute traumatic painful 
condition like fractures. It is also useful in acute sciatica, lumbosciatica and 
chronic low back pain. It can decrease the opioid requirement when used as an 
adjunctive analgesic in patients with cancer pain. It can decrease the headache 
episodes in the migraine patients. 
b. Anti inflammation – it improves pain and functional disability in 
osteoarthritis, ankylosing spondylitis and rheumatoid arthritis. 
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c. Herpetic stromal keratitis – Experimental study in mice demonstrated the  
down regulation of NF-kappa B activation produced protective effect against 
herpetic stromal keratitis. 
d. others – used in rheumatoid arthritis for inhibition of release of superoxide 
from polymorphs and inhibition of release of platelet derived growth factor 
from platelets
56
.   
Drug Interactions - Lornoxicam metabolism is inhibited by clonazepam and 
diazepam and it does not interact with ranitidine and antacids. Co-
administration of lornoxicam and anticoagulants or platelet aggregation 
inhibitors may prolong the bleeding time. It also increases the hypoglycemic 
effect of sulphonylureas and decrease the efficacy of diuretics and ACE 
inhibitors. Cimetidine co-administration inhibits elimination of lornoxicam 
with significant increase in steady state Cmax and reduction in plasma 
clearance. It decreases plasma digoxin clearance and increases methotrexate 
concentration
57
.   
Dosage and administration - The most common dosages of lornoxicam used 
in clinical trials are 4 mg twice or 3 times daily or 8 mg twice daily (orally) for 
management of arthritic conditions, low back pain and ankylosing spondylitis. 
For the management of postoperative pain single or repeated doses of 4 or 8 mg 
(orally or intravenously) lornoxicam is used. Quick-release formulation and 
injectable formulations of lornoxicam is available and it is also available in 
powder form as vial of 8mg for intramuscular and intravenous use. The powder 
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is  dissolved in 2ml water for injection immediately prior to use. As an 
intramuscular injection lornoxicam must be administrated in more than 5 
seconds
56,57
. 
Tolerablility - Lornoxicam has a characteristic tolerability profile of NSAIDs, 
with gastrointestinal disturbances (pain, dyspepsia, nausea, vomiting) being the 
most prominent events. The tolerability of oral lornoxicam appeared to be 
similar to that of diclofenac and better than that of indomethacin in patients 
with arthritic conditions or chronic low back pain in comparative clinical trials. 
Lornoxicam is  better tolerated than parenteral opioid analgesics in patients 
with postoperative pain
59
.  
CLINICAL STUDIES RELATED TO LORNOXICAM  
Many studies show that lornoxicam is effective and well tolerated in the 
treatment of many acute painful conditions like acute sciatica/lumbosciatica, 
acute low back pain and acute post-operative pain following gynaecological, 
orthopaedic   or other surgeries. Lornoxicam has been used in several clinical 
trials for postoperative pain relief after various  surgical procedures. 
Arslan et al studied the postoperative analgesic effect of lornoxicam 
after thyroidectomy in a placebo controlled randomized trial by using a dose of 
8mg intravenous at the end of surgery followed by 8mg twice a day for 24 
hours postoperatively. Authors concluded that pain scores and the incidence of 
nausea and vomiting decreased with the use of lornoxicam. 
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Lornoxicam is more than a decade old NSAID and it has been recently 
introduced in India. A small number of preliminary placebo-controlled and 
comparative clinical studies shows that lornoxicam provides effective analgesia 
following surgery
45
.  
Lorenz et al reported that intravenously administered lornoxicam 
suppressed pain induced brain activation in all regions except hippocampus 
which was shown in a Functional magnetic resonance imaging ( FMRI).  
Yakhnoet et al studied the variation in formulations and found that 
lornoxicam administered as quick formulation was non inferior to equivalent 
formulation of diclofenac in pain relief 
59
. 
Sener et al in a prospective placebo controlled, double blind, 
randomized  study compared the efficacy of lornoxicam with diclofenac , 
ketoprofen and dipyrone for acute postoperative pain management in post 
septoplasty patients. Lornoxi8cam 8mg and diclofenac 75mg twice daily, 
ketoprofen 100mg twice daily, dipyrone 1gm thrice daily and placebo twice 
daily showed no significant difference between four groups
60
.                                                        
Sapolya et al studied the analgesic effects of lornoxicam after total 
abdominal hysterectomy in a randomised double blind study where tramadol is 
used as patient controlled analgesia. They concluded that a single oral dose of 
lornoxicam given preoperatively enhanced the analgesic effect of tramadol 
thereby decreasing the consumption of tramadol and side effects and shortened 
the length of hospitalization
61
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Daglar et al conducted a study to compare the efficacy  and tolerability 
of lornoxicam and diclofenac in pain management after coronary artery bypass 
grafting (CABG) . The study concluded that the efficacy of lornoxicam and 
diclofenac were similar in postoperative pain management and both the study 
drugs were well tolerated
5
.  
In a study done by Mohamed Daabiss et al in analgesia in day care ENT 
surgery the efficacy of lornoxicam in patient receiving intravenous lornoxicam 
8mg or 16 mg before induction with fentanyl was studied. The study revealed 
that lornoxicam 16mg is comparable to fentanyl as an intraoperative 
intravenous analgesia and it was found that lornoxicam was more effective than 
fentanyl in preventing  early postoperative pain patients undergoing minor to 
moderate day care ENT surgical procedure
6
. 
CLINICAL STUDIES RELATED TO DICLOFENAC: 
                 Anirban et al in a clinical study on post‑operative analgesia in 
patients undergoing lower abdominal gynecological surgeries ,between 
injection Diclofenac 75mg intramuscularly and injection Paracetamol 1gm 
intravenously 8
th
 hourly for 24 hours postoperative period showed that injection 
Diclofenac given intramuscularly was superior to intravenous Paracetamol in 
terms of rescue analgesic requirement. The study also showed that the 
combination of intramuscular Diclofenac and intravenous Paracetamol had no 
added advantage over Diclofenac intramuscularly given alone
62
.  
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Ashima Taneja et al in a comparative study on the effect of Paracetamol, 
Diclofenac and their combination in post-operative relief of cesarean section 
concluded that balanced analgesia with combination of Diclofenac and 
Paracetamol considered as the preferred method for postoperative pain 
following cesarean section
63
. 
Cengiz Kara et al in a clinical study on the analgesic efficacy and safety 
of Non steroidal anti inflammatory drugs administered  as intramuscular 
diclofenac in comparison with intravenous paracetamol after transurethral 
resection of prostate (TURP)  showed that single dose of diclofenac alone is 
more effective for pain relief than single infusion of paracetamol
64
.  
With the above extensive literature review there is lack of studies on the 
comparison of lornoxicam with diclofenac in the management of postoperative 
pain, so this study was designed to compare the efficacy and safety of injection 
Lornoxicam given twice daily with twice daily dose of injection Diclofenac for 
3 days in the  management of postoperative pain following Mastoidectomy 
surgery.  
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                                           AIM OF THE STUDY  
Aim of the present study is to evaluate the efficacy and safety of the 
analgesic, Lornoxicam when compared to Diclofenac in the management of   
postoperative pain following mastoidectomy surgery.                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         
  
 
METHODOLOGY 
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                                MATERIALS AND METHODS 
STUDY TYPE: 
        Interventional clinical  study. 
STUDY DESIGN: 
         Prospective,  single blind, randomized, parallel group study. 
STUDY PERIOD: 
         April 2014 – May 2015  
STUDY CENTRE: 
         It is a single centered study conducted in the patients undergoing 
Mastoidectomy Surgery in the Department of Ear Nose Throat, Tirunelveli 
Medical College Hospital, Tirunelveli. 
STUDY DURATION: Three days for each individual patient 
SAMPLE SIZE: Total of 80 patients (40 patients in Lornoxicam group and 40 
patients in diclofenac group)  
INCLUSION CRITERIA:  
 Patients of both sex. 
 Patients aged >18 years and < 70 years. 
 Patients undergoing Mastoidectomy surgery  
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EXCLUSION CRITERIA: Patients with the following criteria are excluded 
from the study. 
 Patients Hypersensitive to drugs 
 Patients with Bronchial asthma, Hypertension  
 Patients with Diabetes mellitus, Peptic ulcer disease and Seizure. 
 Patients with the history of Substance abuse. 
 Patients with Liver and /or Kidney disease.  
 Patients receiving NSAIDS, Sedatives and Hypnotics or Psychotropic 
drugs. 
 Patients with the history of Bleeding diathesis 
 Pregnant and lactating mother. 
WITHDRAWAL CRITERIA: 
 Noncompliance with protocol 
 Protocol deviation 
 Request for withdrawal by the patients 
 Adverse effects ( decision about with drawl from the study was made 
either by patient or investigator ) 
ETHICAL CONSIDERATION:  
            Approval from the Institutional Ethical committee was obtained. 
Written informed consent was obtained in local vernacular language from 
every patient before enrollment. 
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SCHEDULE OF STUDY: 
Screening and Recruitment: 
             The subjects were enrolled based on inclusion criteria after screening. 
During enrollment clinical assessment and the following base line 
investigations were done. 
 Complete blood count 
 Bleeding time and clotting time 
 Random blood sugar 
  Blood urea 
  Serum creatinine 
 Liver function tests  
Randomisation : 
                     After enrollment subjects were randomized into two groups           
( group A and group B) with the help of computer generated random table. 
Treatment Protocol :   
           The patients in this study after randomisation  received postoperative 
analgesics as follows : 
Group A:   Injection  Lornoxicam 8mg given intramuscularly twice daily for 
3days.  
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Group B:   Injection Diclofenac 75mg given intramuscularly twice daily for 
3days.   
In both the groups first dose of the analgesic was given to all the study 
patients immediately after the skin closure and the rest of the doses were given 
every twelve hours for three days.                             
      Pain assessment  
Visual analogue scale (VAS) and Wong Baker FACES pain rating scale 
(WBS) was used to measure the pain level. VAS is a 10cm horizontal line 
graduated scale with 0 to 10, 0 is no pain and 10 is worst pain.  Patients were 
asked to assess their pain on their own and mark on the VAS. Interpretation of 
scoring is 0 to 0.4cm is no pain, 0.5 to 4.4cm is mild pain, 4.5 to 7.4cm is 
moderate pain and 7.5 to 10 cm is severe pain
7
 . The pain assessment with 
WBS was done  with six facial expressions suggesting various pain intensities. 
The first pain assessment was done 1hour after the patient received the 
first dose of  the drug.   Following which pain assessments were done after 
3hours, 6hours, 12hours, 24 hours, 48 hours and 72 hours.  
      Rescue medication: 
                   Any medication used to treat pain after initiation of analgesics is 
rescue medication.  Injection Paracetamol was used as the rescue drug in this 
study. After giving the study drug, when the patient complained of severe pain 
and if the VAS score was more than 7 and WBS more than 8, injection 
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Paracetamol 300mg was given intramuscularly to the patients. Number of 
patients requiring   rescue drug and time when rescue drug was needed by the 
patients were noted in each study group.  
Follow up:  
                    Follow up was done on the day of surgery 1hour, 3 hour, 6 hour 
and 12 hour following the first dose of anti-inflammatory drug. On the first 
postoperative day, approximately 24 hours after the administration of first dose 
follow up was done. Similarly on the second and third postoperative day, 
approximately 48 hours and 72 hours respectively the follow up was done.  
                   During the follow up, VAS and WBS scoring was done and 
physical examination including vital signs like pulse rate, blood pressure and 
temperature were noted. Patients were also enquired about adverse events and 
use of rescue medication and time to use rescue medication through three 
postoperative days.  
EFFICACY PARAMETERS 
  Primary endpoints: Analysis of postoperative pain using 
 10cm visual analogue scale (VAS) pain score 
 Wong Baker FACES pain rating scale (WBS) pain score. 
 
Secondary endpoints: 
 The usage of rescue medication by the patients  
 Time to use the rescue drug by the patients in each 
study group. 
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SAFETY ASSESSMENTS: 
                      Any adverse events reported by the subject or noted by the 
clinician during the each follow-up visit were recorded. In case of treatment 
emergent adverse event, the subject could be withdrawn if continuation of the 
drug was considered harmful. Any adverse event was considered as serious if it 
was fatal, life threatening, disabling or if it prolonged the hospitalization of the 
subject. 
LABORATORY ASSESSMENTS:  
                                Blood samples were obtained preoperatively and on the 
third post-operative day. Parameters assessed were the hemodynamic 
properties like hemoglobin, total blood count, differential count, erythrocyte 
sedimentation rate, platelet count, bleeding time, clotting time and random 
blood sugar. Other parameters measured are liver function test like direct, 
indirect and total bilirubin, alanine transaminase (ALT), aspartate transaminase 
(AST) and alkaline phosphatase and even the albumin, globulin and total 
proteins were measured. Renal function test like blood urea and serum 
creatinine were also measured.  
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STATISTICAL ANALYSIS: 
Statistical  analysis  was  performed  with  the  help  of  statistical  package  
SPSS (Statistical  Package  for  the  Social  Sciences)  version  11 .  
 Baseline  characteristics  of  both  the  groups  were  tabulated  
by  descriptive  statistics (mean , standard  deviation)  and  
frequency  table. They  were  matched  by  unpaired  student  't'  
test  and  Pearson's  chi - square  test . 
 Between the two groups the analysis of primary parameters 
was done using student unpaired ‘t’ test at 1 hour, 3 hour, 6 
hour, 12hour, 24hour, 48 and 72 hour of the study. 
 The time to use rescue medication was expressed in mean and 
standard deviation and the proportion of patients required 
rescue medication  and their association between two groups 
were done using Pearson chi square. 
 The adverse effects were expressed in percentage and the 
association between two groups were done using Pearson chi 
square. 
     To compare two groups,  p  values  less  than  0.05 (p<0.05)  was  
considered       as  significant  in  two  tailed  condition. 
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PATIENT DISPOSITION: CONSORT DIAGRAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                    
 
 
                 Patients screened 
n= 92 
Patients enrolled and Randomised  
n= 80 
Excluded n=12 
Not satisfying 
inclusion criteria  
              
 
Group A Inj.Lornoxicam8mg 
n=40 
Group B Inj.Diclofenac 75mg 
n=40 
Completed study 
n= 40 
Completed study  
n= 40 
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RESULTS 
 
  For a period of one year April 2014 to May 2015, 92 patients (44 male 
patients and 48 female patients) were assessed for eligibility based on the 
inclusion and exclusion criteria. 80 patients were enrolled for the study and 
they were  randomised in to group A and group B .Group A ( n = 40) received 
injection Lornoxicam 8mg and group B (n = 40) received injection Diclofenac 
75mg. Out of these 80 patients 40 patients in group A and 40 patients in group 
B  completed the study. 
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TABLE -1 
BASELINE CHARACTERISTICS 
BASELINE 
PARAMETERS  
INJ.LORNOXICA
M 
GROUP A 
n = 40 
INJ.DICLOFENA
C 
GROUP B 
n=40 
  P VALUE 
Age yrs (mean/SD)      29.72 ± 9.21 
 
     28.42 ± 7.54 
 
   0.492 
 
 
Gender  
 n (%) 
 
 
 
Male 
       
       19 (47.5%) 
 
 
        21 (52.5%) 
        
       19 (47.5%) 
 
  
        21 (52.5%) 
 
 
 
 
 
 
 
 
Female 
 
Weight (Kgs) 
(mean/SD) 
 
65.52 ± 5.12 
 
64.52 ± 5.79 
 
0.416 
 
Duration of Surgery 
 ( min ) (mean/SD) 
 
91.12 ± 12.88 
 
88.50 ± 10.07 
 
0.313 
 
 
Hb (%)(mean/SD) 
 
WBC (cells/cumm) 
(mean/SD) 
 
Platelet count 
(lakhs/cumm) 
(mean/SD) 
 
13.56 ± 1.47 
 
8490 ± 1274.16 
 
 
2.93 ± 0.65 
 
 
 
 
13.6 ± 1.35 
 
8112.5 ± 1294 
 
 
2.77 ± 0.63 
 
 
 
 
0.9 
 
0.192 
 
 
0.26 
 
 
Blood sugar (gms%) 
(mean/SD) 
92.07 ± 9.09 
 
93.45 ± 9.72 
 
0.516 
 
 
Table 1 shows the baseline characteristics of both the groups.  Baseline 
characteristics were similar in both the groups (p>0.05).     
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FIGURE 3 
MEAN AGE OF TWO GROUPS 
 
 
 
 Figure 3 shows the pictorial diagram of mean age distribution between 
two groups. 
  In lornoxicam group the mean age was 28.42 years and the mean age in 
diclofenac group was 29.72 years  
 Both the groups were comparable with no statistically significant 
difference.  
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FIGURE 4 
SEX DISTRIBUTION OF TWO GROUPS 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4 shows the diagrammatic representation  of  the sex distribution 
of two groups in the study. 
   19% were males in both the groups and 21% were females. 
 Both the groups were comparable with  no significant difference 
between two groups. 
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FIGURE 5 
                                 MEAN WEIGHT OF TWO GROUPS 
 
 Figure 5   Shows  the  pictorial  representation  of  the  mean  weight  of 
the two groups.  
 The mean weight in lornoxicam group was 65.52 kg and in diclofenac 
group 64.52 kg. 
  Both the groups were comparable with no significant difference 
between the two groups.  
 
 
 
79 
 
 
PRIMARY EFFICACY PARAMETERS 
TABLE – 2 
VAS PAIN RESPONSE RATES 
VAS INJ LORNOXICAM 
GROUP A 
INJ 
DICLOFENAC 
GROUP B 
P VALUE 
    MEAN ± SD    MEAN ± SD 
VAS_1    2.42    ±   0.87    5.62    ±   1.16 < 0.0001* 
 
VAS_3     1.9     ±   0.81    5.17    ±   0.98 < 0.0001* 
 
VAS_6     1.7     ±    0.88    5.17    ±   1.39 < 0.0001* 
 
VAS_12     1.72   ±    0.98    5.07    ±    1.28 < 0.0001* 
 
VAS_24     1.77   ±    0.91     4.35   ±    1.02 < 0.0001* 
 
VAS_48     1.1     ±    0.84     3.85   ±    0.97 < 0.0001* 
 
VAS_72     0.47   ±   0.75     2.65   ±    1.16 < 0.0001* 
 
* p value <0.05, statistically significant  
 Table 2 shows the visual  analogue scale score comparison of efficacy of 
Lornoxicam and Diclofenac. 
 Lornoxicam produced significant reduction in the postoperative pain 
than diclofenac at 1hr, 3hr, 6hr, 12hr, 24hr, 48hr, 72hrs. (p<0.0001). 
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FIGURE –6 
MEAN (SD) VAS PAIN RELIEF SCORES IN THE STUDY 
POPULATION 
 
 Figure 6 shows the  graphical representation of VAS score of 
Lornoxicam and Diclofenac group. 
  Pain relief was assessed using  visual analog scale (0 - no pain to 10-
worst pain imaginable) 
 Both the groups showed reduction in pain throughout the study and the 
pain reduction was more with lornoxicam group. 
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                                    PRIMARY EFFICACY PARAMETERS 
TABLE – 3 
WBS PAIN RESPONSE RATES 
VAS INJ 
LORNOXICAM 
GROUP A 
INJ DICLOFENAC 
GROUP B 
P VALUE 
    MEAN ± SD    MEAN ± SD 
VAS_1    2.42    ±   0.87    5.62    ±   1.16 < 0.0001* 
 
VAS_3     1.9     ±   0.81    5.17    ±   0.98 < 0.0001* 
 
VAS_6     1.7     ±    0.88    5.17    ±   1.39 < 0.0001* 
 
VAS_12     1.72   ±    0.98    5.07    ±    1.28 < 0.0001* 
 
VAS_24     1.77   ±    0.91     4.35   ±    1.02 < 0.0001* 
 
VAS_48     1.1     ±    0.84     3.85   ±    0.97 < 0.0001* 
 
VAS_72     0.47   ±   0.75     2.65   ±    1.16 < 0.0001* 
 
 
* p value <0.05, statistically significant  
 Table 3 shows the Wong Bakers  pain scale score comparison of 
efficacy of Lornoxicam and Diclofenac.  
 Lornoxicam produced significant reduction in the postoperative pain 
than diclofenac at 1hr, 3hr, 6hr, 12hr, 24hr, 48hr, 72hrs. (p<0.0001) 
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                                                 FIGURE -7 
MEAN (SD) WBS PAIN RELIEF SCORES IN THE STUDY 
POPULATION 
 
 
 
 
 
 
 
 Figure 7 shows the graphical representation of WBS pain score of 
Lornoxicam and Diclofenac group.  
 During the first 12 hour period maximum reduction of pain  was seen in 
6
th
 hour in lornoxicam group and 12
th
 hour of diclofenac group.  
 The reduction in pain score is more in lornoxicam group than diclofenac 
group throughout the study.  
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SECONDARY PARAMETERS 
TABLE- 4 
PROPORTION OF PATIENTS REQUIRED RESCUE MEDICATION 
 
 
GROUPS 
    RESCUE          MEDICATION 
                 REQUIRED 
 
  P VALUE 
 
       YES 
 
NO 
 
GROUP A 
 
 
 
         3(7.5%) 
 
          37(92.5%) 
 
        
 
 
        0.019
* 
 
GROUP B 
 
 
 
        11(27.5%) 
 
        29(72.5%) 
 
* p value <0.05, statistically significant  
 Table 4 shows the proportion of patients who required rescue 
medication in both the study groups. 
 In study group A (lornoxicam) 3 patients required rescue 
medication and in study group B (diclofenac) 11 patients required 
rescue medication. 
 More number of patients in diclofenac group required rescue 
medication than the lornoxicam group which was statistically 
significant. 
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SECONDARY PARAMETERS 
TABLE - 5 
TIME TO USE RESCUE MEDICATION 
 
 
GROUPS 
 
 
NUMBER OF 
PATIENTS 
 
TIME TO USE  RESCUE 
MEDICATION 
(hrs) 
 
MEAN ±  S.D 
 
 
Group A 
 
 
3(7.5%) 
 
7.33  ±  2.51 
 
Group B 
 
 
11(27.5%) 
 
7.09  ±  3.36 
 
 Table 5 shows the mean time to use rescue medication  
 In lornoxicam group the mean time to use rescue drug was 7.33 ±   
 2.21 hours after the first dose  
 In diclofenac group the mean time required to use rescue  
 medication  was 7.09 ± 3.36 
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FIGURE - 8 
TIME TO USE RESCUE MEDICATION OF 2 GROUPS 
 
 
 
 Figure 8 shows the pictorial representation of number of patients 
required rescue drugs  and time to use the rescue drug. 
 The above graph  shows that in diclofenac group, 2 patients 
required rescue medication at 3 hours after  first dose, 6 patients 
required rescue medication 6 hours following the first dose of the drug 
and 2 patients at 12 hours following the first dose. 
 In lornoxicam group only one patient required rescue medication 
at 5hours, 6hours and 10 hours. 
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  Based on the comparison of trend line between the two groups, 
more number of patients utilised the  rescue drugs  in the diclofenac 
group between 3
rd
 to 12
th
 hour following first dose than lornoxicam 
group.  
 The maximum number of patients who required rescue medication 
was in diclofenac group in the 6
th
 hour following the first dose of 
analgesic. 
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TABLE – 6 
RENAL AND LIVER FUNCTION  PARAMETERS OF LORNOICAM 
GROUP 
 
 
 Table 6 shows the Renal and Liver function  test of  lornoxicam 
group 
 The renal function test like blood urea and serum creatinine  in 
study patients of lornoxicam group  showed no significant difference 
between the preoperative and postoperative values.  
                                   
 
 
 
PARAMETERS 
PREOPERATIVE 
Mean ± SD 
POSTOPERATIVE 
Mean ± SD 
PVALUE 
Serum Creatinine 
mg/dl 
0.76 ± 0.07 0.77 ± 0.08 0.279 
Blood Urea mg/dl 25.02 ± 2.06 25 ± 2.14 0.959 
ALT U/L 28.67 ± 2.67 29.35 ± 2.55 0.202 
AST U/L 22.60 ± 2.12 22.47 ± 2.89 0.835 
ALKP U/L 49.25 ± 1.80 49.90 ± 1.82 0.128 
Total BilirubinU/L 0.71 ± 0.6 0.72 ± 0.6 0.881 
Total ProteinU/L 6.86 ± 0.45 6.84 ± 0.34 0.757 
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TABLE – 7 
RENAL AND LIVER FUNCTION PARAMETERS OF DICLOFENAC 
GROUP 
 
 
PARAMETERS 
PREOPERATIVE 
Mean ± SD 
POSTOPERATIVE 
Mean ± SD 
PVALUE 
Serum Creatinine mg/dl 0.77 ± 0.10 0.78 ± 0.10 0.706 
Blood Urea mg/dl 24.5 ± 2.17 24.67 ± 1.71 0.594 
ALT U/L 28.62 ± 2.24 28.52 ± 2.33 0.851 
AST U/L 22.17 ± 2.53 21.47 ± 2.57 0.248 
ALKP U/L 50.47 ± 1.50 50.15 ± 4.09 0.668 
Total BilirubinU/L 0.73 ± 0.21 0.77 ± 0.29 0.244 
Total ProteinU/L 7.02 ± 0.26 7.05 ± 0.19 0.573 
                            
  Table 7 shows the Renal and Liver function  parameters of  
diclofenac group 
  There was no signinificant difference between the preoperative 
and postoperative values of renal and liver function test in 
diclofenac group of study population.  
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ADVERSE EFFECTS 
 All the patients in both the groups completed the study. Both drugs were well 
tolerated. No serious adverse events were noted in two groups. The common 
adverse effects noted are tabulated below.   
TABLE - 8 
NUMBER OF PATIENTS WITH SPECIFIC ADVERSE REACTION 
 
 
 
 
 
 
 
 
 
   Table 8 shows that in diclofenac group, 7 (17.5%) patients 
developed nausea and epigastric pain, 1 (2.5%) patient developed 
vomiting and constipation .  
  In lornoxicam group 2 (5%) patients developed nausea and 
dizziness and 1 (2.5%) developed drowsiness.   
                                                     
 
  ADR GROUP A 
n / (%) 
GROUP B 
n / (%) 
 
Nausea 
 
     2  ( 5 ) 
     
     7 (17.5) 
 
Vomiting  
 
     - 
 
     1 ( 2.5 ) 
 
Epigastric pain 
     
     - 
 
     7 (17.5 ) 
 
Dizziness  
  
     2 ( 5 ) 
 
     - 
 
Constipation  
 
    - 
 
     1 (2.5) 
 
Drowsiness  
 
     1 (2.5) 
 
     - 
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FIGURE – 9 
PATIENTS WITH COMMON ADVERSE REACTION IN TWO 
GROUPS 
 
 
 
 Figure 9 shows the adverse reaction that occurred in two 
groups during the study period. 
 In diclofenac group the  most common adverse reaction  
developed  was nausea and epigastric pain. 
 In lornoxicam group the most common adverse reactions 
developed was nausea and   dizziness 
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                                            DISCUSSION  
 Effective postoperative pain management is an important concern for 
anesthesiologist and surgeon
65
. Approximately 80% of patients undergoing 
surgical procedures experience mild to severe post-operative pain, despite the 
major improvements in the understanding of post-operative pain pathology
7
.  
Mastoidectomy is one of the common surgical procedures done under 
local anasthesia in the department of otorhinolaryngology.  The most 
frequently used NSAID in the management of postoperative pain is diclofenac 
and they are associated with increased incidence of adverse effects like 
abdominal pain, dyspepsia, heartburn, gastrointestinal ulcer and diarrhea
66
.  
Lonoxicam is a NSAID with high therapeutic potency of oxicams with reduced 
gastrointestinal toxicity when compared to other group of its class
1
. So the 
present study was carried out to compare diclofenac with lornoxicam. When 
oral administration is not possible or rapid analgesia is needed following 
surgery parentral route of administration is the route of choice
67
. Therefore the 
preferred route of administration of analgesic in this study was intramuscular 
route. 
Lornoxicam has been used successfully in prevention and treatment of 
post-operative pain and it has been shown to be as effective as morphine, 
meperidine and tramadol
6
. Lornoxicam as well as diclofenac have been used 
for post-operative pain relief in various surgical procedures and these drugs are 
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used individually or in combination with other drugs using different rescue 
drug in different studies
7
. 
In our study the mean age of the patients in lornoxicam group was 29.72 
± 9.21 years and in the diclofenac group it was 28.42 ± 7.54 years with no 
significant difference between the two groups. The mean age was similar to 
another study conducted by Geetha Bhandari et al
68
.  The sex distribution in the 
present study was equally distributed between both the groups with male 
patients of 19 (47.5%) and female patients of 21 (52.5%) in group A and group 
B. This showed that during our study period female patients who underwent 
mastoidectomy surgery were more than males. This was similar to another 
study conducted by Dae Wook et al on mastoidectomy patients
69
. The mean 
weight of patients in both the groups were 65.52 ± 5.12 kg and 64.52 ± 5.79 in 
lornoxicam and diclofenac respectively with no significant difference between 
the two study groups. The mean weight was similar to study conducted by Dae 
Wook et al
69
.  
In the present study administration of lornoxicam for acute 
postoperative pain following mastoidectomy surgery resulted in statistically 
significant (p value <0.0001, table2 and 3) decrease in VAS score and WBS 
score throughout the study when compared to patients who received diclofenac. 
The maximum reduction of pain intensity in the first 12 hour period was 6 hour 
following the first dose of lornoxicam   and 12 hours following first dose of 
diclofenac. This showed the earlier onset of action of the drug lornoxicam. This 
is comparable to study done by sudip et al in comparative study of efficacy and 
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safety of lornoxicam versus tramadol as analgesics after surgery on head and 
neck showed that lornoxicam had early onset action
1
. VAS and WBS has been 
used to evaluate the efficacy of pain management of acute postoperative pain   
because of its defining pain intensity and reliability
67
. The present study is 
similar to study done by Galani Varsha et al, in which   lornoxicam and 
diclofenac were compared in patients with acute postoperative pain after spinal 
surgery the result showed significantly greater analgesic effect by lornoxicam 
at 30 minutes and 300 minutes when compared to diclofenac
7
. Similar to our 
study there are few studies available comparing the efficacy and safety of 
lornoxicam and diclofenac, Vishalkumar et al studied the efficacy and safety of 
lornoxicam and diclofenac in osteoarthritis knee patients the results showed 
that lornoxicam significantly relieved pain more than diclofenac
59
. Sushila 
godara et al conducted a study by comparing lornoxicam and diclofenac in the 
management of acute renal colic and concluded that both the drugs are equally 
effective and safe with added advantage of lornoxicam being more effective in 
early period
70
. 
In the present study total number of patients required paracetamol as   
rescue medication was n=14(17.5%).   In group A (lornoxicam)  n=3(7.5%) 
and in group B (diclofenac) n=11(27.5%)(Table 4).  Patients  required  rescue 
analgesics following the first dose of the study drug in both the groups and the 
total rescue analgesic drug consumption was less in lornoxicam group when 
compared to diclofenac group. Similarly the utilisation of rescue drug was   less 
with the drug lornoxicam in a study conducted by Sudip et al
1
. The difference 
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was highly significant (p<0.019, Table 4) showing better efficacy of 
lornoxicam when compared to diclofenac.  
The time taken to use the first rescue medication in lornoxicam group 
was five hours and three hours in diclofenac group  after the first dose of the 
study drug (Table 5),  which showed the earlier utilisation of the rescue 
medication in diclofenac group.  This is similar to study by Girija et al in which 
lornoxicam was compared with tramadol as postoperative management in 
patients undergoing elective gynecological surgery the results revealed that 
there was significant difference in time for rescue medication requirement 
between two groups . The time taken to utilise  the first rescue analgesic was 
longer in lornoxicam (194.96±103.94 min) than the tramadol group 
(159.44±70.4 min) and the consumption of rescue analgesic was less in 
lornoxicam group (63.6±17.8) when compared to tramadol (64.2±21.86) 
group
71
. 
In the present study no patients dropped out from the study due to 
adverse effects. Totally 21 (26.25%) patients developed adverse effect in both 
the groups, 5(12.5%) patients in lornoxicam group and 16 (40%) patients in 
diclofenac group. Significantly more patients developed adverse reaction in 
diclofenac group (p <0.005, Table 6) which showed the better safety and 
tolerability of lornoxicam when compared to diclofenac.  
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The occurrence of nausea and epigastric pain (Table 7) was more in 
diclofenac group as compared to lornoxicam group. 7(17.5%) patients 
developed nausea and epigastric pain in diclofenac group and 2 patients 
developed nausea and no patients developed epigastric pain in lornoxicam 
group. This was supported by Nagendra S Chunduri et al in a study, efficacy of 
aceclofenac and diclofenac for relief of postoperative pain after third molar 
surgery which showed that nausea and epigastric pain were more in diclofenac 
group compared to aceclofenac group
66
. 
Dizziness and drowsiness were seen in 2 (5%) and 1(2.5%) patients 
respectively in lornoxicam group but no patients developed drowsiness and 
dizziness in diclofenac group. Dizziness seen in lornoxicam group could be one 
of the complications of mastoidectomy surgery
72
. Galani Varsha et al, also 
showed that lornoxicam had high tolerability and less gastrointestinal 
toxicity
7
.In another comparative study in healthy volunteers lornoxicam 
16mg/day showed significantly less gastrointestinal injury which was verified 
endoscopically when compared to naproxen 1000mg/day
45
. 
In the present study the Renal function parameters, blood urea and 
serum creatinine and liver function parameters like AST, ALT, alkaline 
phosphatase, total protein and total bilirubin did not show any significant 
variation after 72 hours as compared to baseline in both the groups. This was 
similar to study conducted by Turhan Togrul et
67
. In the present study the renal 
function parameters and liver function parameters were studied over a short 
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span of 72 hours, the nephrotoxicity and hepatotoxicity of these drugs cannot 
be commented in the present study. 
However the difference between  studies could be due to varying dosing 
schedule of lornoxicam and because of different types of surgical procedures.  
Lornoxicam, has been recently introduced in India and few number of placebo 
controlled and comparative clinical studies have shown that lornoxicam as an 
effective analgesic following surgery
45
.  
From the above results it was evident  that lornoxicam (8mg twice daily) 
was found to be a better analgesic in terms of efficacy and tolerability when 
compared to diclofenac (75mg twice daily)in the management of postoperative 
pain following mastoidectomy surgery under local anesthesia .    
The study population in both the groups showed satisfactory 
compliance.  The limitations in our study were that, the subjects were not 
followed up after discontinuation of the drug for delayed adverse reaction. The 
present study was single blinded study with fairly small number of patients.  So 
further studies with larger sample size, double blind design and long term 
follow up are necessary to investigate, further   the effectiveness of drugs in 
relieving pain after mastoidectomy surgery.   
                          
       
                                  
97 
 
CONCLUSION 
Based on the results of our study we conclude that injection lornoxicam 
8mg given intramuscularly is a better analgesic when compared to injection 
diclofenac 75 mg given intramuscularly in efficacy and tolerability in the 
management of   postoperative pain following mastoidectomy surgery.  
 
 
ABBREVIATIONS 
IASP   - International association for study of pain 
ATP   - Adenosine tri phosphate 
TRP   - Transient receptor potential 
PTX3   - Pentraraxin-3 
GABA  - Gamma aminobutyric acid 
ORL   - Opioid receptor like 
TNF   - Tumour necrosis factor 
IL   -         Interleukin 
AA   - Arachidonic acid 
PG   - Prostaglandins 
NOS   - Nitric oxide synthase 
NRS   - Numeric rating scale 
VAS   -  Visual analog scale 
VRS   - Verbal rating scale 
FPS-R   - Faces pain scale – Revised 
WBS   - Wong bakers pain rating scale 
PAG   - Periaqueductal grey 
NSAID  - Nonsteroidal anti-inflammatory drug 
MOR   - Mu opioid receptor 
KOR   - Kappa opioid receptor. 
ALKP   - Alkaline phosphatase 
AST                        - Aspartate transaminase. 
ALT   - Alanine transaminase. 
COX   - Cycloxygenase 
NAPQI  - N-acetyl-p-benzoquinone imine 
5HT   - 5 Hydroxy tryptamine 
PCA   - Patient controlled analgesia  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX – I 
INFORMED CONSENT FORM 
 
Study Title - A Comparative study of Efficacy and Safety of Lornoxicam 
and Diclofenac as Postoperative Analgesics after Mastoidectomy Surgery 
Study Number  ___________________________________ 
Subject's Full Name ___________________________________ 
Date of Birth/Age ___________________________________ 
Address  ___________________________________ 
 
1. I confirm that I have read and understood the information sheet dated for 
the above study and have had the opportunity to ask questions. OR I have 
been explained the nature of the study by the Investigator and had the 
opportunity to ask questions. 
 
2. I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason and without my 
medical care or legal rights being affected. 
 
3. I understand that the sponsor of the clinical trial/project, others working on 
the Sponsor's behalf, the Ethics Committee and the regulatory authorities 
will not need my permission to look at my health records both in respect of 
the current study and any further research that may be conducted in relation 
to it, even if I withdraw from the trial. However, I understand that my 
Identity will not be revealed in any information released to third parties or 
published. 
 
4. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) 
 
5.  I agree to take part in the above study 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative: ____________________ 
Signatory's Name _____________________________ Date __________ 
Signature of the Investigator ____________________ Date ___________ 
Study Investigator's Name _____________________ 
Signature of the Witness ______________________ Date ________________ 
Name of the Witness 
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Utßm ûPdú[ô©]ô¡u TXu Utßm TôÕLôl× Ï±jÕ Ko Jl×VoÜ BnÜ. 
 
TeÏ ùßTY¬u ùTVo :  
 
TeÏ ùTßTY¬u YVÕ :  
  TeÏ ùTßTYo CRû] 
Ï±dLÜm 
1 Sôu úUúX Ï±l©hÓs[ UÚjÕY Bn®u ®YWeLû[ 
Sôu T¥jÕ ×¬kÕ ùLôiúPu. GuàûPV NkúRLeLû[ 
úLhLÜm ARtLô] RÏkR ®[dLeLû[ ùT\Üm 
YônlT°dLlThÓs[Õ G] A±kÕ ùLôiúPu.  
 
2 Sôu CqYôn®p Ru²fûNVôL Rôu TeúLt¡ú\u. GkR 
LôWQj§]ôúXô GkR LhPj§Ûm, GkR NhP £dLÛm 
EhTPôUp Sôu CqYôn®p CÚkÕ ®X¡ ùLôs[Xôm 
Gußm A±kÕ ùLôiúPu.  
 
3 CkR BnÜ NmTkRUôLúYô. CûRf NôokÕ úUÛm BnÜ 
úUtùLôsÞm úTôÕm CkR Bn®p TeÏ ùTßm 
UÚjÕYo GuàûPV UÚjÕY A±dûLûV TôolTRtÏ 
GuàûPV AàU§ úRûY«pûX G] A±kÕ 
ùLôs¡ú\u. Sôu Bn®p CÚkÕ ®X¡d ùLôiPôÛm 
CÕ ùTôÚkÕm G] A±¡ú\u. 
 
4 CkR An®u êXm ¡ûPdÏm RLYûXúVô. Ø¥ûYúVô 
TVuTÓj§d ùLôs[ UßdL UôhúPu. 
 
5 CkR Bn®p TeÏ ùLôs[ Jl×d ùLôs¡ú\u. G]dÏ 
ùLôÓdLlThP A±ÜûWL°uT¥ SPkÕ ùLôsYÕPu 
BnûY úUtùLôsÞm UÚjÕ A¦dÏ EiûUÙPu 
CÚlúTu G] Eß§V°d¡ú\u. Gu EPp SXm 
Tô§dLlThPôúXô. ApXÕ G§oTôWôR YZdLj§tÏ Uô\ô] 
úSônÏ± ùRuThPôúXô EPú] CûR UÚjÕY A¦«Pm 
ùR¬®lúTu G] Eß§ A°d¡ú\u.  
 
 
TeúLtTY¬u ûLùVôlTm /……………..…….. CPm ……………….. úR§ ................ 
LhûP ®Wp úWûL  
TeúLtTY¬u ùTVo Utßm ®XôNm ……………………………………………...……… 
BnYô[¬u ûLùVôlTm /……………..…….. CPm ……………….. úR§ ................ 
BnYô[¬u ùTVo ………………………………………………………………………….. 
ûUVm ………………………………………………………………………………………… 
Lp®V±Ü CpXôRYtÏ (ûLúWûL ûYjRYoLÞdÏ) CÕ AY£Vm úRûY  
Nôh£«u ûLùVôlTm /……………..…….. CPm ……………….. úR§ ................ 
ùTVo Utßm ®XôNm ………………………………………………………………….  
  
Appendix –I 
 
úXôo]ôf£Lm UÚjÕY Bn®p TeúLtTRtÏ A±®l×  
Utßm Jl×Rp T¥Ym. 
 
Sôu ___________________ G]Õ úUvPônÓ GÛm× AßûY 
£¡fûNdÏ ©\Ï Y− Ïû\l× UÚkÕ úXôo]ôd£Lm ùLôÓjR©u, ©u 
®û[ÜLs YW Yôn×Ls Es[Õ G] UÚjÕYo êXm A±kÕ 
ùLôiúPu. JqYôûU, Y«ßY−, Yôk§, £ß¿WLm Utßm LpÄWp 
Tô§l× HtlTP Yônl× Es[Õ GuTûRÙm A±kÕ ùLôiúPu.  
 AßûY £¡fûNdÏl©u úXôo]ôd£dLj§u SuûULs Utßm 
©u®û[ÜLs A±kÕ £¡fûNdÏ ØÝ U]ÕPu NmURm A°d¡ú\u.  
 
 
ûLùVôlTm,  
 
 
 APPENDIX – II 
PROFORMA 
GROUP: 
Patient’s Name:                                          Date:         
Age:                                                            Sex: 
Weight: 
Diagnosis: 
Type of surgery:                                          Duration of surgery: 
History: 
1. HT/DM/Asthma/seizure/bleeding diathesis 
2. Liver /kidney disease / peptic ulcer  
3. Hypersensitivity to drugs  
4. Substance abuse/ Smoking  
5. Drug intake – NSAID, sedatives, hypnotics, Psychotropic drug 
6. Pregnancy / lactation  
7. Previous surgery 
8.Time of giving the test drug: 
9. Name of the Drug given: 
 
 
 
 
 
PAIN SCORE AND VITAL SIGNS 
 
 1hr 3hr 6hr 12hr 24hr 48hr 72hr 
VAS        
WBS        
PR        
RR        
BP        
Temp        
 
Adverse reaction : 
 
Adverse events/ complaints (if any)  
 
 
 
 
          
 
 
 
 
  
Hemodynamic parameters 
 
 
 
Liver function test: 
 
 
 
 Hb% TC DC ESR BT CT 
Base line       
72 hrs after 
surgery 
      
 Total  
protein 
Total  
bilirubin 
ALT AST ALK 
PHOS 
Base line      
72 hrs after 
surgery 
     
  
Other parameters: 
 
      
 
 
 
 
 
 
Usage of rescue medication: Yes/No 
 
Time to use rescue medication: 
 
 
 
 
   
 Blood  
sugar 
Serum  
creatinine 
Blood  
urea 
Base line    
72 hrs after surgery    
S.No Age Sex Group 
Weigh
t 
SUR - 
Type
DUR - 
MIN
 VAS 
_1
VAS_3 VAS_6
VAS_1
2
VAS_2
4
VAS_4
8
VAS_7
2
WBS_
1
WBS_
3
WBS_
6
WBS_
12
WBS_
24
WBS_
48
WBS_
72
PR_1 PR_3 PR_6 PR_12 PR_24 PR_48 PR_72 SBP_1
1 24 2 A 60 1 90 2 2 3 3 2 0 0 2 2 2 2 2 0 0 80 76 70 70 74 74 70 110
2 27 2 A 58 1 90 2 2 3 3 2 1 1 2 2 4 2 2 0 0 80 74 78 70 74 70 74 110
3 40 2 A 68 1 90 1 3 2 1 1 1 0 2 2 2 2 2 0 0 76 74 74 74 74 74 74 114
4 23 2 A 62 1 90 2 3 1 3 3 2 2 2 2 2 2 2 0 0 80 74 74 76 80 80 80 114
5 19 1 A 64 1 90 4 3 4 4 2 2 2 4 4 4 4 2 2 2 80 80 84 80 74 74 78 118
6 18 1 A 59 1 90 4 4 3 3 3 2 2 4 4 4 4 4 2 2 74 74 70 78 78 80 80 110
7 33 2 A 65 1 90 3 3 2 2 2 1 0 4 4 2 2 2 2 0 70 70 78 78 70 80 80 112
8 21 1 A 72 2 120 2 2 3 4 2 1 0 2 2 2 4 2 2 0 72 70 74 76 70 70 76 112
9 25 1 A 68 2 90 2 2 2 2 3 1 0 2 2 2 2 2 0 0 74 74 74 78 78 78 80 110
10 19 2 A 56 1 60 2 2 2 2 3 1 0 2 2 2 2 2 0 0 80 76 80 80 84 84 80 110
11 22 1 A 70 2 90 2 2 2 2 3 1 0 2 2 2 2 2 2 0 80 80 76 76 80 80 80 110
12 29 2 A 59 2 90 1 3 1 1 2 2 0 2 4 2 2 2 2 0 80 80 76 74 74 80 74 114
13 47 2 A 72 1 90 2 1 1 1 3 3 1 2 2 2 2 2 2 0 80 80 76 76 76 80 80 114
14 20 1 A 60 1 90 2 1 1 1 0 0 0 2 2 2 2 0 0 0 80 80 80 80 74 74 74 110
15 25 1 A 64 1 90 4 2 2 2 1 0 0 4 2 2 2 2 0 0 80 80 76 76 78 78 78 114
16 29 2 A 59 1 90 1 3 1 1 2 2 0 2 4 2 2 2 2 0 70 70 72 80 78 78 74 110
17 47 2 A 72 2 90 2 1 1 2 2 2 0 2 2 2 2 2 2 0 74 70 70 70 70 78 74 110
18 19 2 A 58 2 120 4 2 2 1 2 1 0 4 2 2 2 2 2 0 70 78 80 80 74 70 70 120
19 20 1 A 65 1 90 3 2 2 1 2 1 1 4 2 2 2 2 2 2 80 80 74 76 80 80 80 110
20 34 1 A 68 1 90 2 2 2 3 3 2 2 2 2 2 4 4 2 2 80 80 76 76 76 76 76 110
21 26 2 A 60 1 90 4 2 2 2 4 2 1 4 2 2 2 4 2 2 80 84 80 77 80 80 74 110
22 42 2 A 65 1 90 3 2 2 2 2 2 1 4 2 2 2 2 2 0 76 74 72 80 78 78 74 112
23 28 2 A 65 1 75 2 2 2 3 2 2 2 2 2 2 4 2 2 0 74 74 74 70 70 72 70 112
24 35 1 A 68 1 75 2 2 3 3 2 2 2 2 2 4 4 2 2 2 70 70 72 70 74 74 70 114
25 19 1 A 70 2 90 2 2 0 1 2 0 0 2 2 0 2 2 0 0 82 70 74 74 74 72 70 110
26 28 1 A 72 1 90 2 2 2 1 1 1 0 2 2 2 2 2 2 0 84 70 74 74 80 82 80 110
27 29 2 A 66 2 90 2 2 2 2 2 1 0 2 2 2 2 2 2 0 80 70 70 72 74 70 70 100
28 21 2 A 58 1 90 2 0 1 2 2 2 0 2 0 2 2 2 2 0 70 72 70 74 74 70 70 100
29 37 2 A 69 1 75 2 0 0 1 2 2 0 2 0 0 2 2 2 0 72 74 70 74 70 70 72 110
30 22 1 A 64 1 90 2 1 0 0 1 0 0 2 2 0 0 2 0 0 70 72 74 74 72 70 72 110
31 49 2 A 70 1 90 3 2 2 1 1 1 1 4 2 2 2 2 2 2 72 74 74 74 72 70 74 110
32 47 2 A 65 2 90 2 2 2 0 0 0 0 2 2 2 0 0 0 0 70 72 74 74 72 70 72 112
33 23 1 A 68 1 75 3 1 1 1 1 1 0 4 2 2 2 2 2 0 70 70 72 74 70 72 74 110
34 27 1 A 63 1 90 2 1 1 1 1 0 0 2 2 2 2 2 0 0 70 74 72 74 70 72 70 112
35 34 1 A 72 2 90 4 2 2 2 0 0 0 4 2 2 2 0 0 0 70 74 72 72 70 74 70 110
36 27 1 A 60 1 90 3 2 2 1 1 0 0 4 2 2 2 2 0 0 74 72 70 72 70 70 72 112
37 46 2 A 68 1 75 2 2 1 1 1 0 0 2 2 2 2 2 0 0 74 72 70 72 70 70 70 110
38 38 2 A 74 1 90 2 1 1 1 1 1 0 2 2 2 2 2 2 0 74 74 70 70 70 74 72 120
39 36 1 A 73 1 75 4 2 1 1 1 0 0 4 2 2 2 2 0 0 74 70 72 70 74 70 76 110
40 34 1 A 72 2 90 2 1 1 1 1 1 1 2 2 2 2 2 2 0 74 70 72 76 78 70 78 110
Group A - Injection Lornoxicam 8 mg
SBP_3 SBP_6
SBP_1
2
SBP_2
4
SBP_4
8
SBP_7
2
DBP_1 DBP_3 DBP_6
DBP_1
2
DBP_2
4
DBP_4
8
DBP_7
2
HB_B TC_B
DC 
N_B
DC 
L_B
DC 
E_B
ESR_B PLA_B BT_B CT_B
DIRB_
B
INDIR
B_B
TOTB_
B
ALT_B AST_B
ALKP_
B
TOTP_
B
110 120 100 110 110 110 74 74 78 80 80 78 78 13.4 7,500 60 35 5 15 2.57 1.3 2.8 0.5 0.3 0.8 32 22 52 7
110 118 118 120 120 118 78 74 74 70 74 74 78 11.1 7100 50 45 5 14 2.23 1.2 2.3 0.4 0.3 0.7 32 24 50 7.2
110 110 110 120 118 120 74 78 78 70 70 74 72 13.8 9,100 55 45 5 12 3.3 2.55 3.3 0.4 0.3 0.7 30 25 49 7
118 120 120 118 120 120 80 82 82 78 80 80 82 12.5 8800 64 31 5 14 3.42 3.4 3.15 0.4 0.4 0.8 25 19 48 7.2
118 120 120 118 120 120 70 74 74 74 74 74 74 15.1 9800 63 34 3 14 3.66 1.4 2.2 0.3 0.3 0.6 26 25 49 7.5
110 114 120 110 112 110 70 74 74 70 70 70 70 14 7900 50 47 3 12 3.09 1.5 2.3 0.3 0.3 0.6 25 24 48 7.2
110 110 110 108 110 110 68 70 72 76 78 78 76 13.2 9700 58 39 3 15 2.38 1.3 3.3 0.3 0.3 0.6 27 22 52 7
110 108 110 114 110 110 68 72 70 70 74 74 70 15.3 7500 57 37 6 15 2.67 3 4 0.4 0.3 0.7 28 22 52 6.8
110 110 118 120 120 110 76 78 80 76 80 82 80 15.3 8900 58 40 2 15 2.79 2.3 3.5 0.2 0.5 0.7 27 21 50 7.3
110 108 108 110 110 108 70 76 76 72 70 70 70 12.8 9400 61 35 4 15 3.84 2.2 3.3 0.3 0.4 0.7 32 21 52 6.1
110 110 110 112 112 112 70 70 70 72 72 74 74 15.8 7300 55 42 3 14 2.12 2.23 4.35 0.5 0.2 0.7 26 20 51 6.4
110 112 110 112 110 110 76 70 72 74 74 70 70 13.3 6700 63 34 3 15 2.2 3.1 3.5 0.4 0.4 0.8 32 20 47 6.2
112 114 114 112 118 110 78 70 74 74 76 74 74 11.2 6200 57 40 3 14 3 2.5 3.45 0.4 0.4 0.8 32 22 48 6.8
110 114 112 112 112 114 78 80 78 78 80 80 80 13.2 7000 60 36 4 15 2.69 1.4 3.2 0.4 0.3 0.7 30 24 47 7.4
110 110 114 112 112 112 80 70 70 70 70 76 76 11.2 7700 55 40 5 12 2.68 1.35 2.5 0.5 0.3 0.8 32 24 48 6.5
110 110 116 114 110 110 70 80 70 74 80 74 74 15 9200 58 38 4 14 3.3 2.6 3.3 0.3 0.4 0.7 28 25 47 7.2
110 112 118 118 118 120 80 76 74 76 80 78 74 13.4 8400 65 31 4 14 2.54 1.36 4.2 0.4 0.4 0.8 26 20 52 6.2
118 120 118 118 120 120 84 74 72 74 76 80 74 15 6600 58 40 2 14 1.75 1.5 3.2 0.4 0.3 0.7 30 22 50 6.2
110 112 110 118 110 120 84 80 74 74 70 70 70 14.2 9600 74 23 3 13 3.79 2.5 4.2 0.4 0.4 0.8 28 24 50 7
118 118 120 120 114 120 80 80 78 70 74 74 74 15.5 7700 66 32 2 14 2.28 1.45 2.5 0.4 0.3 0.7 30 22 52 7.4
110 112 110 110 112 114 80 80 84 80 80 80 80 11.6 9300 60 35 5 15 1.97 1.4 2.5 0.4 0.2 0.6 32 21 50 7
114 112 112 112 114 120 78 78 80 80 84 80 80 11.5 5300 71 26 3 12 2.39 1.3 3.2 0.4 0.2 0.6 27 20 51 7.4
112 114 110 112 112 112 78 78 78 78 80 80 80 14.8 8400 70 28 2 12 2.65 2.4 3.2 0.2 0.4 0.6 26 25 50 6.8
114 116 116 116 114 110 78 78 78 80 80 84 80 13.2 7600 72 26 2 14 2.27 2.15 2.45 0.4 0.4 0.8 26 20 47 6.4
112 110 110 110 112 112 80 84 80 78 78 80 84 15.7 9500 60 35 5 14 2.17 1.25 2.45 0.3 0.4 0.7 32 25 47 6.2
110 110 114 110 110 110 82 80 80 80 80 78 78 14.1 7000 55 42 3 12 3.05 1.35 3 0.5 0.3 0.8 30 24 48 6.8
108 108 110 110 108 110 82 80 78 80 74 76 78 11.5 8500 68 30 2 14 2.93 2.15 4.45 0.3 0.5 0.8 30 24 48 6
110 110 108 110 110 110 82 80 74 80 74 78 80 11.8 6000 61 35 4 14 1.51 2 4.3 0.4 0.4 0.8 25 25 52 6.2
118 118 120 118 118 118 80 80 80 74 74 74 70 11.2 8000 70 28 2 15 4.09 1.35 2.4 0.4 0.3 0.7 32 25 48 6.2
112 110 108 110 110 110 80 84 84 84 82 80 80 13.4 9700 51 45 4 14 2.68 2.3 3.4 0.5 0.3 0.8 28 24 47 6.2
118 118 110 120 120 118 82 82 80 80 82 80 84 12.9 6400 58 37 5 14 3.11 2.2 3.4 0.3 0.4 0.7 30 25 48 7.1
110 110 110 112 114 112 84 84 84 86 80 80 80 13.8 9500 63 36 1 15 4.46 4 4.05 0.4 0.3 0.7 32 25 50 7.4
114 110 112 114 112 110 74 74 80 70 80 80 80 15 9800 66 32 2 12 2.45 2.2 3.3 0.4 0.3 0.7 25 20 50 7.3
114 110 112 114 114 110 80 82 78 70 70 70 70 15 6900 60 39 1 12 2.15 2.4 3.2 0.3 0.4 0.7 25 18 48 6.8
112 110 112 110 114 110 78 78 78 80 78 78 80 14.5 6100 53 44 3 14 2.48 1.2 3.35 0.4 0.3 0.7 30 20 47 7.4
114 112 114 110 110 112 80 80 80 82 78 76 76 15.5 9800 63 34 3 14 2.81 2.5 4.3 0.4 0.3 0.7 32 25 47 7.1
110 112 114 112 112 112 70 70 70 72 72 74 74 13.1 9900 54 45 1 12 3.18 2.3 3.2 0.4 0.2 0.6 30 24 50 7.1
118 110 110 112 110 110 70 74 70 70 70 70 74 11.2 9100 65 31 4 14 3.26 2.4 3.1 0.4 0.3 0.7 25 20 47 7.1
110 112 112 114 114 114 74 74 74 72 72 72 72 14.4 8200 65 32 3 14 2.65 3 4.45 0.4 0.3 0.7 26 22 51 7.2
110 112 110 110 112 112 74 74 72 72 74 74 74 14 7400 68 30 2 12 2.4 2.3 3 0.4 0.3 0.7 26 24 50 7.2
Group A - Injection Lornoxicam 8 mg
ALB_B GLO_B SUG_B CRE_B URE_B HB_72 TC_72
DC 
N_72
DC 
L_72
DC 
E_72
ESR_7
2
PLA_7
2
BT_72 CT_72
DIRB_
72
IND_7
2
TOTB_
72
ALT_7
2
AST_7
2
ALKP_
72
TP_72
ALB_7
2
GLOB_
72
SUG_7
2
CRE_7
2
URE_7
2
RES 
DR
TI  
RE(HR
)
ADR
4 3 79 0.9 25 13.2 7800 66 30 4 15 2.8 1.2 3 0.3 0.4 0.7 27 22 49 7 4 3 80 0.9 25 2 0 1
4 3.2 103 0.8 26 11 7200 56 39 5 14 1.98 1.1 2.15 0.5 0.3 0.8 27 24 50 6.8 3.8 3 103 0.8 28 2 0 2
4 3.5 101 0.8 27 13.2 7500 59 36 5 12 2.56 2 3.1 0.4 0.3 0.7 31 22 48 7.1 4.1 3 90 0.8 26 2 0 1
4.2 3 96 0.8 25 12 8300 65 30 5 14 3.33 3.2 3 0.4 0.2 0.6 28 21 52 7.2 4.2 3 96 0.8 25 1 5 2
4 3.5 106 0.8 22 14.9 8800 67 32 1 12 3.64 1.4 2.2 0.4 0.3 0.7 27 20 49 7 4 3 84 0.7 26 2 0 2
4 3.2 81 0.8 28 14.2 7900 50 47 3 14 3.09 1.3 2.2 0.4 0.4 0.8 28 22 52 7.2 4 3.2 80 0.8 22 2 0 2
4 3 95 0.8 25 13.5 9100 58 38 4 14 2.35 1.5 3.4 0.4 0.4 0.8 31 22 52 6.2 3.2 3 98 0.9 28 1 7 2
4 2.8 92 0.7 27 15 6900 60 37 3 15 2.08 2.5 3.45 0.4 0.2 0.6 28 22 47 6.4 4.2 2.2 95 0.7 25 2 0 2
4.3 3 103 0.7 28 14.9 8400 58 40 2 14 2.25 2 2.8 0.3 0.4 0.7 27 21 52 7 4 3 86 0.7 23 2 0 2
4.2 1.9 86 0.8 22 12 9400 62 36 2 15 3.25 2.15 3.2 0.5 0.3 0.8 32 23 52 6.8 4.4 2.4 95 0.8 26 1 10 1
4.1 2.3 88 0.8 24 14.2 7000 56 42 2 14 1.89 2.2 4.35 0.4 0.3 0.7 28 22 48 6.4 4.4 2 88 0.8 26 2 0 2
3.8 2.4 102 0.7 26 12.8 6200 56 40 4 15 1.3 3 2.45 0.4 0.4 0.8 40 25 52 6.8 4 2.8 100 0.8 28 2 0 2
4.3 2.5 95 0.7 25 10.8 5800 56 42 2 15 2.36 2.55 3.5 0.4 0.3 0.7 30 20 49 6.9 4 2.9 100 0.7 28 2 0 2
4.6 2.8 85 0.7 27 12.8 6800 56 40 4 14 2.18 1.5 3.4 0.5 0.3 0.8 31 25 48 7 4 3 94 0.9 24 2 0 2
4 2.5 110 0.8 28 11.2 7400 63 36 1 14 2.14 1.3 2.5 0.7 0.4 0.7 31 28 52 7.2 4.2 3 102 0.9 28 2 0 1
4.2 3 90 0.7 25 14.5 8800 56 42 2 14 2.68 2.25 3 0.4 0.2 0.6 32 20 50 6.8 3.5 3.3 90 0.7 20 2 0 2
4 2.2 84 0.8 25 13 8000 64 32 4 14 2.05 1.3 4.25 0.4 0.3 0.7 28 18 52 6.8 4.1 2.7 80 0.8 26 2 0 2
4.1 2.1 81 0.7 21 15.8 6400 59 39 2 14 1.72 1.4 2.45 0.4 0.3 0.7 29 27 48 7 4.4 2.6 92 0.8 25 2 0 2
4 3 107 0.9 22 13.9 9400 70 25 5 14 3.24 2.45 4.1 0.3 0.5 0.8 27 18 52 6.4 3.2 3.2 95 0.8 25 2 0 2
4.4 3 110 0.8 26 15.5 7300 65 30 5 12 2.08 1.4 2.45 0.4 0.2 0.6 27 18 48 7 4 3 110 0.9 26 2 0 2
4.5 2.5 84 0.8 28 13.6 8100 68 30 2 13 2.2 2.45 3.4 0.4 0.4 0.8 28 22 48 7.2 4.6 2.6 95 0.8 28 2 0 2
4 3.4 112 0.8 26 12.8 7200 74 24 2 14 2.16 2 2.3 0.3 0.4 0.7 28 24 52 7.4 4.6 2.8 95 0.8 22 2 0 2
4.2 2.6 95 0.8 22 15.2 9800 60 36 4 13 2.14 2 2.3 0.4 0.3 0.8 32 24 48 6.4 3.8 2.6 104 0.8 26 2 0 1
4 2.4 84 0.6 24 13.8 6800 55 42 3 14 2.85 1.4 2.4 0.3 0.4 0.7 32 18 52 7 4.9 2.1 100 0.7 23 2 0 2
4.2 2 94 0.8 25 10.9 7400 73 26 1 14 2.42 2.3 4.2 0.4 0.4 0.8 27 18 48 6.4 4.9 1.5 95 0.8 22 2 0 2
4.5 1.3 94 0.8 23 11.2 5600 56 41 3 15 1.2 2.3 4.45 0.3 0.3 0.6 32 20 47 6.4 4.8 1.6 94 0.8 24 2 0 2
4.4 1.6 106 0.6 21 10.9 8500 73 26 1 15 2.93 2.15 4.2 0.3 0.4 0.7 30 20 48 6.4 4.9 1.5 100 0.6 22 2 0 2
4.4 1.8 82 0.7 27 11.2 5600 56 40 4 14 1.2 2.3 4.45 0.3 0.5 0.8 27 22 49 6.4 4.8 1.6 94 0.8 24 2 0 2
4.1 2.1 84 0.8 26 10.9 8400 72 29 1 16 3.85 2 2.5 0.3 0.4 0.7 28 23 52 6.4 4.3 2.1 90 0.8 26 2 0 2
4.2 2 95 0.8 25 12.9 9400 54 42 4 12 2.84 2.45 3 0.4 0.3 0.7 30 25 48 6.2 4.2 2 95 0.7 22 2 0 2
4.1 3 100 0.7 24 11.5 7000 57 38 5 14 2.58 2 3.2 0.3 0.4 0.7 31 20 50 7 4 3 95 0.6 28 2 0 2
4.2 3.2 102 0.8 27 13.2 9400 62 37 1 14 3.45 3.4 4 0.4 0.2 0.6 32 23 52 7.2 4.2 3 95 0.7 25 2 0 2
4.2 3.1 85 0.8 26 14.8 9400 64 34 2 12 2.45 2.2 3.3 0.5 0.2 0.7 30 27 50 6.5 3.3 3.2 85 0.7 25 2 0 2
4 2.8 78 0.6 22 14.5 6200 56 42 2 14 2.2 2.45 3 0.4 0.3 0.7 28 25 50 7 4.2 3.2 88 0.6 25 2 0 2
4.5 2.9 100 0.6 26 14.2 6000 58 39 3 12 2.52 2 3.2 0.4 0.3 0.7 28 25 52 7.1 4.1 3 95 0.9 22 2 0 2
4 3.1 94 0.8 22 14.8 9400 61 37 2 14 2.9 1.45 4.2 0.3 0.4 0.7 28 20 52 7 4 3 88 0.8 25 2 0 2
4.2 2.9 84 0.7 24 12.8 9600 54 45 1 14 2.54 2.2 3 0.4 0.3 0.7 27 28 50 7.2 4.2 3 94 0.8 28 2 0 2
4.1 3 94 0.8 28 11 9400 67 32 1 12 3.18 2.2 3 0.3 0.4 0.7 27 22 48 7.3 4.2 3.1 95 0.7 22 2 0 2
4.3 2.9 79 0.7 26 14.2 8600 62 34 4 12 2.42 2.4 3.3 0.2 0.4 0.6 28 28 48 7 4 3 85 0.8 25 2 0 2
4.2 3 98 0.9 25 14 7400 68 30 2 14 2.4 2.3 3.4 0.3 0.4 0.7 32 25 50 7.2 4.2 3 98 0.8 26 2 0 2
Group A - Injection Lornoxicam 8 mg
S.No Age Sex Group 
Weigh
t 
SUR - 
Type
DUR - 
MIN
 VAS 
_1
VAS_3 VAS_6
VAS_1
2
VAS_2
4
VAS_4
8
VAS_7
2
WBS_
1
WBS_
3
WBS_
6
WBS_
12
WBS_
24
WBS_
48
WBS_
72
PR_1 PR_3 PR_6 PR_12 PR_24 PR_48 PR_72 SBP_1
1 18 1 B 65 1 90 8 4 2 3 5 3 3 8 4 2 2 6 4 4 94 100 80 80 90 80 80 110
2 22 2 B 58 1 90 10 8 4 4 7 6 1 10 8 4 4 6 6 2 96 110 90 90 100 90 80 100
3 27 1 B 65 2 120 8 8 8 6 4 4 2 8 8 8 6 4 4 2 100 110 110 90 94 84 84 120
4 18 2 B 56 1 90 5 5 8 6 3 2 2 6 4 8 6 4 2 2 100 90 100 84 84 80 80 110
5 21 1 B 60 1 90 5 5 5 4 3 3 2 6 6 6 4 4 4 2 94 94 90 84 84 76 78 110
6 19 2 B 62 1 90 5 5 6 6 4 2 2 6 6 6 6 4 2 2 90 90 90 84 90 84 90 110
7 35 2 B 60 1 90 6 5 8 7 6 6 5 6 6 8 8 6 6 4 100 96 100 90 90 80 80 100
8 34 2 B 70 1 60 5 5 4 5 4 4 2 6 6 6 6 4 4 2 80 80 76 80 80 82 82 110
9 19 2 B 60 1 90 5 5 6 4 4 4 3 6 6 6 4 4 4 2 80 80 84 80 80 84 80 110
10 27 2 B 64 1 90 6 5 4 4 4 4 3 6 6 6 4 4 4 2 80 80 80 84 84 80 76 110
11 35 1 B 68 1 90 5 5 4 8 2 3 2 6 6 4 8 2 4 2 80 80 84 86 86 86 80 110
12 31 1 B 72 1 90 5 5 5 5 5 4 2 6 6 6 6 6 4 2 80 84 82 82 82 80 76 110
13 33 1 B 75 1 90 5 4 4 4 3 3 2 6 4 4 4 4 4 4 80 84 84 80 82 80 80 110
14 27 2 B 58 1 75 7 6 5 4 4 4 4 8 6 6 4 4 4 4 80 84 84 80 80 84 84 110
15 19 1 B 62 2 90 5 5 5 8 5 4 3 6 6 6 8 6 4 4 80 86 84 80 80 84 82 110
16 35 2 B 62 2 120 4 4 4 5 4 4 2 4 4 4 6 4 4 2 80 80 84 84 86 80 80 110
17 35 2 B 63 1 90 7 5 5 4 4 3 2 8 6 6 4 4 4 2 80 84 84 80 80 84 80 110
18 25 2 B 62 1 90 5 4 4 4 4 4 2 6 4 4 4 4 4 2 80 84 84 86 80 86 84 110
19 22 2 B 59 2 120 5 5 5 4 4 2 2 6 6 6 4 4 2 2 80 84 86 84 84 84 84 110
20 45 2 B 60 1 90 6 6 5 5 4 4 2 6 6 6 6 4 4 2 80 84 84 86 84 84 80 110
21 25 1 B 76 2 90 6 5 5 5 5 4 2 6 6 6 6 4 4 2 86 84 80 74 76 74 80 112
22 35 2 B 62 1 90 5 4 4 5 4 4 3 6 4 4 6 4 4 4 80 84 80 84 82 80 80 110
23 30 2 B 68 2 120 6 5 4 3 3 4 2 6 6 4 4 4 4 2 80 80 80 78 80 84 84 120
24 40 2 B 62 1 90 5 5 4 4 4 4 3 6 4 4 4 4 4 3 80 80 84 84 82 82 82 110
25 32 2 B 64 1 90 6 6 6 6 5 4 2 6 6 6 6 6 4 2 84 84 84 82 80 82 80 112
26 33 1 B 75 1 90 5 6 5 5 5 4 4 6 6 6 6 6 4 4 80 80 84 82 84 80 80 112
27 34 1 B 68 1 90 6 5 5 5 5 5 4 6 6 6 6 6 6 4 70 74 80 80 78 80 80 110
28 20 1 B 62 1 90 5 4 6 6 5 5 4 6 4 6 6 6 6 4 80 80 84 82 84 84 84 110
29 32 1 B 68 1 90 5 4 7 6 5 5 5 6 4 8 6 6 6 4 80 84 84 84 84 86 86 110
30 25 1 B 62 1 90 6 6 6 6 5 5 4 6 6 6 6 6 6 4 80 84 84 84 82 84 84 110
31 19 2 B 54 2 90 6 7 6 5 4 4 2 6 8 6 6 4 4 2 80 84 80 84 84 84 80 112
32 45 2 B 68 1 75 4 5 6 6 5 5 4 4 6 6 6 6 6 4 86 88 88 88 88 86 80 110
33 29 2 B 56 1 90 5 4 4 6 5 4 4 6 4 4 6 6 4 4 80 78 78 78 78 80 80 110
34 37 1 B 70 2 120 5 5 6 8 6 4 4 6 6 6 8 6 4 4 80 80 84 78 78 78 76 118
35 33 2 B 58 1 75 5 5 4 4 4 4 3 6 6 4 4 4 4 4 78 78 80 80 80 84 80 120
36 19 1 B 64 2 90 4 4 3 3 2 2 0 4 4 4 4 2 2 0 80 80 80 84 84 80 76 110
37 19 1 B 68 1 75 5 5 7 5 4 4 2 6 6 8 6 4 4 2 80 84 84 80 80 76 76 112
38 35 1 B 75 1 75 6 6 5 4 4 2 0 6 6 6 4 4 2 0 80 76 70 74 72 70 70 114
39 25 1 B 75 1 90 6 6 5 5 5 4 2 6 6 6 6 6 4 2 84 76 76 74 70 78 70 110
40 23 1 B 65 2 90 7 6 8 6 6 4 4 6 6 8 6 6 4 4 80 72 74 72 74 80 80 110
Group B - Injection Diclofenac 75 mg
SBP_3 SBP_6
SBP_1
2
SBP_2
4
SBP_4
8
SBP_7
2
DBP_1 DBP_3 DBP_6
DBP_1
2
DBP_2
4
DBP_4
8
DBP_7
2
HB_B TC_B
DC 
N_B
DC 
L_B
DC 
E_B
ESR_B PLA_B BT_B CT_B
DIRB_
B
INDIR
B_B
TOTB_
B
ALT_B AST_B
ALKP_
B
TOTP_
B
110 120 120 120 120 120 70 70 70 74 74 70 70 13.7 10,500 59 26 15 14 2.37 1.58 3.28 0.6 0.5 1.1 32 18 52 7.2
110 110 110 110 120 120 60 60 70 70 70 70 70 12.3 5700 61 33 6 14 1.93 1.4 2.5 0.6 0.6 1.2 30 18 52 7
120 120 120 120 110 110 74 80 84 80 80 80 84 15.2 11,000 72 20 8 15 2.02 1.3 4.25 0.6 0.6 1.1 30 19 51 7.1
120 124 114 120 110 110 70 80 76 74 80 70 70 12.6 8000 62 32 5 14 2.18 1.3 4.2 0.5 0.5 1 32 19 50 7.1
110 120 120 124 120 120 80 80 80 74 74 70 70 15.4 10,500 71 24 5 12 3.1 1.1 2.3 0.5 0.5 1 30 20 52 7.4
110 110 120 112 112 110 70 70 80 70 70 70 70 13.7 7600 60 30 10 16 2.61 1.3 3.5 0.5 0.5 1 30 24 51 7.9
100 110 110 110 110 110 70 70 70 70 80 80 80 13.8 8,800 61 41 8 15 1.78 1 2.15 0.6 0.6 1.2 32 24 52 6.8
110 110 110 110 112 116 70 80 70 70 80 70 70 12.2 9400 60 31 9 16 3.17 2.3 2.5 0.5 0.4 0.9 31 21 52 6.9
110 114 114 110 110 114 70 70 80 80 70 70 70 13.5 8,100 53 41 6 18 2.24 2.2 2.3 0.4 0.6 1 30 21 49 7
110 112 112 110 116 110 70 74 74 70 70 76 76 11.6 9400 60 35 5 15 2.08 1.5 2.3 0.5 0.4 0.9 27 20 52 7.1
110 110 120 114 116 110 80 80 84 84 80 82 80 14.2 8,400 62 34 4 12 3.24 2.2 2.45 0.4 0.2 0.6 27 20 52 7
110 114 120 120 110 110 70 80 80 84 84 80 80 13.8 8200 62 36 2 16 2.45 2.2 3.15 0.3 0.3 0.6 27 20 50 6.8
110 112 120 120 110 120 70 80 84 84 82 80 80 16.4 7,600 52 46 2 15 2.43 1.3 2.5 0.4 0.4 0.8 28 21 50 6.6
110 114 114 120 110 116 70 70 80 80 80 70 74 12.7 7300 56 40 4 16 3.18 1.2 2.45 0.5 0.4 0.9 28 20 52 7.2
110 116 120 114 114 120 74 74 70 70 80 80 74 16 6,400 58 34 8 14 4.45 1.15 2.25 0.4 0.3 0.7 27 22 49 6.8
110 112 110 114 120 120 70 70 70 72 74 72 76 12.4 8600 60 32 8 15 3.4 2 3.4 0.4 0.2 0.6 27 22 50 7
110 110 112 112 110 110 70 70 74 74 74 74 70 12.8 9,400 64 34 2 14 2.68 2.15 3.3 0.2 0.3 0.5 28 22 48 7.1
110 118 116 120 118 118 70 70 74 80 70 70 74 13.7 8200 66 27 7 14 2.92 2.3 3.1 0.2 0.4 0.6 32 24 47 7.2
112 114 114 112 120 120 70 70 80 80 70 80 80 12.4 7,800 58 34 8 15 2.46 1.22 3.45 0.5 0.3 0.8 26 22 52 7.2
110 114 112 114 116 116 70 80 80 80 70 80 80 11.6 8000 52 40 8 16 2.93 2.2 3.4 0.3 0.4 0.7 28 25 52 6.8
112 114 112 120 120 120 76 76 76 74 74 74 80 14.6 8,700 60 31 9 14 4.3 1.15 3.2 0.2 0.3 0.5 26 26 51 6.7
110 114 112 116 118 118 80 78 82 78 78 74 80 12.6 7200 58 34 8 15 3.56 2.15 4 0.4 0.2 0.6 32 25 50 7.1
118 118 120 124 124 120 80 80 84 86 84 80 80 12.8 9,600 64 32 4 14 2.48 2.3 3.2 0.2 0.3 0.5 26 25 50 6.8
110 114 114 118 118 118 78 78 78 80 76 78 78 12.8 8400 64 30 6 16 2.64 2.4 3.2 0.4 0.4 0.8 32 25 52 6.6
110 110 110 112 118 118 72 70 70 74 76 76 76 12.2 8,400 56 40 3 16 3.45 2.15 2.1 0.3 0.5 0.8 26 24 52 7.2
110 112 114 118 118 120 74 74 74 74 70 70 72 15.4 7100 60 32 8 14 2.33 2.4 3.2 0.3 0.2 0.5 27 25 48 6.4
106 106 106 100 106 110 70 70 70 70 72 70 70 17.5 10,100 50 40 10 16 3.44 2.2 3.3 0.4 0.2 0.6 27 25 48 7
110 120 120 120 120 120 70 70 78 80 80 70 70 13.9 8900 65 30 5 15 3.45 2 3.2 0.4 0.1 0.5 26 24 49 7
110 110 120 120 120 110 70 70 76 76 80 80 80 13.8 7,800 67 28 5 12 3.23 2.15 3.2 0.4 0.2 0.6 28 25 50 7.3
110 110 120 120 120 110 70 80 70 70 80 80 70 12.2 6400 45 48 7 14 2.43 2.4 3.2 0.4 0.2 0.6 26 24 51 7.4
110 112 114 114 112 110 70 80 80 70 70 74 70 12.5 10,800 66 30 4 14 3.52 1.3 2.3 0.4 0.2 0.6 30 20 51 7
110 120 120 120 118 110 70 70 74 70 72 70 70 13.4 10200 60 34 6 12 4.19 2.4 3.2 0.4 0.2 0.6 26 25 52 7
110 110 110 118 116 116 70 70 70 74 72 72 70 13.1 10,400 65 30 5 14 3.33 1.1 2.35 0.2 0.2 0.4 27 22 50 7.2
118 120 116 116 110 110 70 72 72 74 74 74 70 13.8 9400 60 34 6 14 2.38 2.4 3.2 0.4 0.2 0.6 26 20 52 7
120 18 118 120 114 114 74 70 74 78 78 74 74 12.1 7,500 58 38 4 15 3.74 2.2 3.4 0.4 0.2 0.6 26 22 50 7.3
110 114 114 116 114 110 70 70 74 74 74 70 70 15.5 7300 56 40 4 15 2.91 1.55 3.22 0.3 0.2 0.5 28 20 50 7.2
112 114 114 114 120 114 70 74 74 70 70 70 70 14.9 8,800 60 38 2 14 3.01 1.1 2.5 0.4 0.3 0.7 30 22 52 6.7
114 114 110 110 112 110 74 70 72 74 70 70 70 13.2 7800 68 28 4 12 2.84 1.45 2.3 0.4 0.2 0.6 32 25 48 7
112 110 110 112 114 114 70 72 70 74 70 70 70 13.8 8,700 60 36 4 14 2.9 1.4 2.5 0.4 0.3 0.7 30 16 48 6.8
112 112 118 110 110 110 70 72 74 70 70 78 78 14 7200 57 40 3 14 3.75 2.3 3.5 0.5 0.3 0.8 32 25 50 7.2
Group B - Injection Diclofenac 75 mg
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2
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ALB_7
2
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2
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DR
TI  
RE(HR
)
ADR
4.2 3 83 0.9 25 13.5 10300 64 25 11 14 2.42 1.52 3.28 0.2 0.5 0.7 27 18 50 7.4 4.3 3.1 80 0.8 26 2 0 2
4 3 93 0.6 20 12 6000 62 32 6 14 1.65 1.5 2.5 0.6 0.6 1.2 26 25 52 6.9 4 2.9 89 0.9 22 1 3 1
4.1 4 89 0.8 24 15 11000 68 24 8 15 2.01 1.3 4.2 0.6 0.5 1.1 32 24 50 6.9 4 2.9 80 0.6 24 1 6 1
4.1 3 89 0.9 22 11.8 7800 65 30 5 15 2 1.15 4.25 0.7 0.8 1.5 28 22 52 7.3 4.2 3.1 90 0.9 24 1 6 2
3.4 4 80 0.8 24 14.8 8100 68 27 5 16 2.86 1.1 2.3 0.4 0.4 0.8 30 21 47 7.2 3 4.2 90 0.8 25 2 0 1
3.5 4.4 92 0.8 26 13.2 7800 58 35 7 12 2.23 1 3 0.5 0.5 1 30 20 52 7.2 2.8 4.4 92 0.8 26 2 0 1
3.4 3.4 105 0.8 20 13.2 8700 52 42 6 16 1.65 1.15 1.3 0.7 0.8 1.5 28 18 48 6.9 3.3 3.6 90 0.7 22 1 6 2
4 2.9 100 0.9 22 11.8 8600 63 24 13 16 2.8 2 2.2 0.6 0.6 1.2 31 18 48 6.8 4 2.8 100 0.9 24 2 0 1
4 3 90 0.6 21 13.3 7300 55 40 5 14 2.18 2.18 2.35 0.5 0.7 1.2 32 19 50 6.8 4.2 2.6 90 0.6 21 2 0 2
4.1 3 94 0.8 25 11.2 9300 61 34 5 15 1.98 2.3 2.45 0.4 0.4 0.8 27 22 49 6.9 4.2 2.6 104 0.9 25 2 0 2
4.2 2.8 90 0.9 24 13.8 8000 64 32 4 14 3.08 2.1 2 0.4 0.3 0.7 27 21 49 6.8 4.2 2.6 95 0.8 22 1 12 2
4.2 2.6 90 0.6 24 13.8 8200 62 36 2 16 2.25 2.15 3.3 0.4 0.3 0.7 28 24 52 6.6 4 2.6 95 0.8 25 2 0 2
4.2 2.4 106 0.9 25 16.4 8000 52 46 2 15 2.68 1.45 2.4 0.3 0.4 0.7 30 24 52 7 4.2 2.8 94 0.8 24 2 0 1
4.2 3 88 0.9 25 11.8 7400 56 40 4 14 2.64 2 3.2 0.4 0.3 0.7 28 25 50 6.9 4 2.9 88 0.8 24 2 0 1
4.4 2.4 106 0.8 28 14.8 7200 56 38 6 16 3.86 2 2.4 0.5 0.3 0.8 28 24 48 6.8 4.2 2.6 101 0.8 26 1 12 2
4.2 2.8 105 0.7 24 12.2 8400 62 30 8 15 2.84 2.2 3.45 0.4 0.3 0.7 27 20 47 7.1 4.3 2.8 95 0.6 26 2 0 2
4.3 2.8 95 0.6 24 12.4 9600 66 32 2 15 2.68 2.15 3.3 0.3 0.3 0.6 27 18 47 7 4.2 2.8 90 0.7 26 2 0 1
4.6 3.2 84 0.8 26 13.8 9000 70 23 7 15 2.92 2.54 3.4 0.3 0.3 0.6 28 22 71 7.2 4.1 3.1 95 0.9 26 2 0 1
4.2 3 90 0.7 27 12.1 8000 48 44 8 15 2.46 1.22 3.45 0.3 0.2 0.5 27 18 48 7 4 3 88 0.8 27 2 0 2
4 2.8 107 0.8 24 11.2 8000 52 40 8 14 2.93 2.2 3.4 0.4 0.2 0.6 28 24 50 7 4 3 96 0.9 25 2 0 1
4.2 2.5 101 0.6 26 14.3 8400 61 34 5 14 3.8 1.2 3.4 0.2 0.2 0.4 28 18 48 7 4 3 109 0.8 25 2 0 1
4.2 2.9 108 0.8 26 12.6 7200 48 44 8 14 3.56 2.15 4 0.4 0.2 0.6 24 25 47 7.1 4.2 2.9 95 0.6 25 2 0 2
4.2 2.6 105 0.9 25 12.7 9900 64 32 4 16 2.59 2.15 3.4 0.2 0.3 0.5 28 19 50 7 4.3 2.7 94 0.8 28 2 0 2
4 2.6 94 0.9 20 12.2 8600 68 27 5 16 2.16 2.15 3 0.4 0.4 0.8 28 25 47 7 4.2 2.8 102 0.8 26 2 0 2
4.1 3.1 90 0.7 26 12.2 8400 56 40 4 16 2.86 2.1 3.4 0.4 0.3 0.7 25 20 48 7 4 3 96 0.8 25 2 0 2
4.2 2.2 86 0.9 26 13.7 6400 60 31 9 15 2.04 2.2 3.4 0.5 0.5 1 27 24 50 6.8 4.4 2.4 82 0.9 22 2 0 1
4.5 2.5 81 0.9 28 17.1 9300 51 44 5 14 2.93 2.4 3.15 0.5 1 1.5 30 20 51 7.2 4.6 2.6 82 0.8 24 2 0 1
4.1 2.9 95 0.5 25 13.9 8750 64 31 5 15 3.42 2.15 3.4 0.4 0.2 0.6 29 24 50 6.9 4 2.9 86 0.6 26 2 0 2
4.2 3.1 108 0.6 26 13.8 7800 70 25 5 14 3.1 2.2 3.4 0.3 0.2 0.5 25 25 52 7.2 4.1 3.1 102 0.8 25 1 6 2
4.2 3.2 77 0.8 27 11.8 6800 53 42 5 15 2.56 2.2 3.4 0.4 0.1 0.5 30 18 47 7.1 4.1 3 90 0.6 25 2 0 2
4 3 91 0.7 27 11.8 10,500 65 31 4 14 2.54 2 2.4 0.3 0.2 0.5 32 20 52 7.2 4.2 3 94 0.6 22 1 3 1
4.2 2.8 89 0.9 23 12.8 9600 54 40 6 15 3.45 2.2 3 0.4 0.3 0.7 36 22 48 7.4 4.3 3.1 82 0.7 24 2 0 2
4.1 3.1 80 0.8 22 12.8 9800 68 27 5 15 2.56 2 2.4 0.3 0.2 0.5 32 19 50 7.1 4.1 3 85 0.9 22 2 0 2
4.5 2.5 90 0.8 22 13.4 9400 60 35 5 14 2.32 2.3 3.4 0.4 0.3 0.7 28 25 59 7.1 4.5 2.6 95 0.9 25 1 12 2
4.1 3.2 99 0.8 24 11.8 7600 60 38 2 15 3.54 2.4 3 0.3 0.2 0.5 30 25 49 7.4 4.3 3.1 95 0.9 26 2 0 2
4.2 3 85 0.8 27 14.8 7200 57 37 6 15 2.45 2 3.15 0.2 0.2 0.4 26 20 52 7.2 4.2 3 90 0.7 26 2 0 2
4 2.7 78 0.7 27 14.8 8400 62 36 2 14 2.8 1.45 2.5 0.4 0.2 0.6 30 22 48 6.8 4.1 2.7 85 0.8 28 1 6 1
4 3 85 0.8 25 13 7800 69 27 4 12 2.75 1.45 2.3 0.4 0.3 0.7 30 19 47 7.2 4.2 3 80 0.9 26 2 0 2
4.1 2.7 80 0.8 26 14.2 8600 60 38 2 14 2.75 2 2.4 0.5 0.3 0.8 28 22 49 7.4 4.2 3.2 90 0.8 25 2 0 2
4.2 3 85 0.8 22 14 7000 58 38 4 12 2.2 2.2 3.5 0.5 0.4 0.9 26 20 50 7.2 4 3.2 100 0.9 22 1 6 1
Group B - Injection Diclofenac 75 mg
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